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CHAPTER 1                                                      
  INTRODUCTION AND PROBLEM STATEMENT 
 
1.1 Motivation and Problem Statement 
 
ADR was defined in [1] as “An appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of a medicinal product; adverse effects 
usually predict hazard from future administration and warrant prevention, or specific 
treatment, or alteration of the dosage regimen, or withdrawal of the product”.                           
ADRs are a major public health problem in the United States [1]. In the year 2010, for 
instance, Adverse Events Reporting System which is managed by the U.S. Food and Drug 
Administration (FDA) shows that 82,724 deaths were attributed to serious adverse drug 
reactions and 471,291 serious cases were reported, which included among others 
hospitalization, life-threatening, and/or disability [2]. Before drugs are marketed, they are 
extensively tested in animals and in clinical trials in humans. Clinical trials often refer to 
pre-marketing studies. Clinical trials have been playing a crucial role in evaluating the 
overall safety and efficacy of new medications before they get into the market. However, 
due to many reasons [1]  the clinical trials are limited in size and duration, and thus are not 
capable of detecting rare ADRs. Given the limited information available when the drug is 
marketed, post-marketing surveillance has become increasingly important. Post-marketing 
surveillance is the process of identifying, reporting, and responding to the issues occurred 
while taking medication[1]. The responding includes actions that can be taken to improve 
product safety and protect the public health, such as labeling changes, safety alerts or 
2 
 
 
product withdrawals [2]. To date, many methods have been adopted in post-marketing 
surveillance systems, The most common  one is  spontaneous reporting systems, such as 
MedWatchTM [3] in FDA. Those systems suffer from low reporting rates, typically less 
than 10%. Underreporting of ADRs is a common issue in post-marketing surveillance 
systems which may delay ADR signal detection and cause underestimation of the size of a 
problem. Paper [4]   explained other limitations including difficulties with adverse event 
recognition, biases and report quality.  
    Data mining techniques and Bayesian methods have been used to facilitate the 
evaluation of ADRs [5]. However, because of  the complexity of its mathematics, the 
unknown features of the data, (i.e., the event background incidences) and the lack 
of consensus about using data mining in medical applications, data mining is not a 
preferred method and its use is still limited [3].      
     Detecting ADR signal pairs is technically a complex problem. This is the case if 
we realistically assume that there does not exist a set of rules that are readily acceptable to 
all human experts (e.g., physicians, epidemiologists and pharmacists). The parameters used 
in identifying the signal pairs are really a vague, subjective measure rather than an 
objective measure. Furthermore, human experts often disagree one another owing to their 
knowledge and experiences and there is no “ground truth” to indicate which physician is 
right or wrong. Because of this and other limitations, current surveillance systems are not 
ideal for rapidly identifying rare unknown ADRs. A more effective system is needed as the 
electronic patient records become more and more easily accessible in various health 
organizations such as hospitals, medical centers and insurance companies. These data 
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provide a new source of information that has great potentials to detect ADR signals much 
earlier.    
     In this dissertation I have developed a multi-agent system to identify adverse 
drug reaction signal pairs (i.e., potential links between drugs and apparent adverse 
reactions). The eventual aim of the system is to helps health organization systems achieve 
earlier identification of potential ADR signal pairs. Intelligent agents may be defined as 
“software programs that act on behalf of users to find and filter information, negotiate for 
services, automate complex tasks, and collaborate with other agents to solve complex 
problems”[6]. Intelligent agents share some common characteristics, including autonomy, 
collaboration, delegation, and communication skills. A set of agents that help one another 
in solving problems by using cooperation, coordination and negotiation techniques is 
called a multi-agent system. 
     The agents are equipped with intelligent decision maker that arms them with the 
rule-based reasoning capability. The reasoning is based on a fuzzy inference system 
implemented using the freeware FuzzyJess [7]. Fuzzy logic is used to represent, interpret, 
and compute vague and/or subjective information which is very common in medicine.  
The developed system design enables the agents to effectively interact and share 
their experiences by setting up an environment for the agents to learn from each other and 
work in a proactive way to identify ADR signal pairs.  The system allows the most 
important and insightful detection rules produced by the most experienced agent (i.e., the 
agent that has the largest amount of patients in its patient database) to bubble up for the 
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benefit of the entire agent community. The rules will be updated over time, leading to 
improved similarity-finding performance.  
 
1.2  Adverse Drug Reaction Overview 
 
Medications have brought better health and longer life to the human race. Every 
day, hundreds of millions of people from all over the world are affected by the medicines. 
However, medicines are not hundred percent risk-free, and are always associated with 
some unexpected Adverse Drug Reactions (ADRs). 
1.2.1  ADR Statistics 
 
ADR appears in 2.4-5.2 per 100 hospitalized adult patients [8]. A study of serious 
ADRs shows that such serious events are between the fourth and sixth leading cause of 
death in the U.S., after heart disease, cancer, accidents, and violence [9]. If the adverse 
event is not serious, such as loss of appetite, allergy or change in mood, it still has an effect 
to the life of the patients. Another study has to analysis the causes of  hospitalization found 
that approximately 1.5 million patients a year were hospitalized were caused by adverse 
drug reactions [9]. This means that around 4,000 patients daily suffer from serious adverse 
drug reactions so they need to enter hospitals. Although a large number of patients are 
admitted to hospital as a result of  adverse events, 57% of these ADRs were not recognized 
at the time of admission [10]. Each ADR may increase the stay at hospitals by 2.2 days for 
a patient case and to lead to an increase in bill by $3,244 per hospital stay [11]. 
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The early detection of ADRs will reduce health care costs approximately by 
$760,000 per year [8]. A study which analyzed a large number of data came from  nursing 
homes concluded that over half of the adverse events are preventable [3]. Here are more 
statistics from [3] to show the importance of detecting ADRs as soon as possible:  
 
 In 1995 medication –related problems in United States cause 199000 deaths per year. 
 In 2001, 140000 deaths in Untied States have been have been estimated in hospitals 
which would make it the third leading cause of death in that year. 
 It has been expected that 0.31 percent of hospitalized patients in the USA die of 
ADRs in 1991. 
 In Olmsted County, 2.9 per cent of patients died in hospitals as result of ADRs in 
1994. 
 In 2000, a New Jersey hospital the death rate due to ADRs was 3.2 percent. 
 In a US hospital during a 2 years monitored period ended at 1994, 109 patients 
suffered from medical consequences as a result of medication-related issues or 
ADRs. These clinical consequences cost $1.5 million. 
 
1.2.2 Types of ADR 
 
Adverse reactions are a recognized hazard of drug therapy. Although some ADRs 
are minor and resolve without consequences, others can cause permanent disability or 
death.  
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The risk of ADRs effects ranges from near zero (with, for example, Nystatin and 
Hydroxocobalamin) to high (with, for example, Immunosuppressive or Antineoplastic 
drugs). In the literature they are using two terms Adverse Event (AE) and Adverse Drug 
Reaction (ADR). The term ‘Adverse event (AE)’ is slightly different from ADRs [12]. AE 
is referred to an adverse outcome that occurs while a patient is taking a drug or at some 
time afterwards, but that may or may not be attributable to the drug [1]. All ADRs are AEs, 
but not all AEs are ADRs. 
ADRs are classified as predictable or unpredictable. Predictable ADRs can be 
related to drug’s pharmacology (i.e., drug interactions) while unpredictable ADRs has not 
to do drug’s pharmacology, (i.e., drug allergy) [13]. 
For example 
Predictable ADRs: 
 Side effects (usually minor and self-limited events). 
 Secondary effects (predictable but not inevitable events). 
 Interactions (effects resulted by using another drug simultaneously). 
 Toxicity (effects of taking drugs with large doses). 
Unpredictable ADRs: 
 Intolerance (very severe side effects). 
 Allergic (unanticipated severe effects, usually appears in weak/not immunized 
patients). 
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Some serious adverse drug reactions are detected after a drug has been on the 
market for a while [1]. Therefore, when a drug is approved and began to be available in 
market, huge numbers of patients will be affected by that potential adverse effect until that 
potential adverse event has been identified. Until now there is no clearly defined process to 
be followed in order to detect adverse events [1] and [3]. In section 1.2.3 the literature of 
the existing ADRs Detection techniques and their problems will be reviewed. 
 
1.2.3 Existing Major ADR Detection Methods 
 
A complete understanding of the safe use of drugs is not possible at the time when 
drug is developed or marketed. At that time, the safety information is only limited on a few 
thousand people in typical clinical trials. For example, people are not aware of the risk of 
heart attacks associated with the use of rofecoxib until five years later after it was launched 
to the market.   
In this section, I briefly introduce several methods for detecting Adverse Drug 
Reactions. Pre- and post market assessments of drugs are important methods used in 
identifying ADR signals pairs. Premarket reviews address the issues of safety of a 
particular drug, and post-marketing surveillance systems check for rare adverse reactions, 
effects that can be identified only with long-term use. 
 
1.2.3.1 Pre-marketing Studies (clinical trial) 
 
Before drugs are marketed, they are extensively tested in the beginning in animals 
then in clinical trials in humans. Clinical trials often called pre-marketing studies. Clinical 
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trials have been playing a crucial role in evaluating the overall safety and efficacy of new 
medications before they get into the market. However, due to many reasons [1, 3, 14, 15], 
some rare or serious ADRs are likely to remain unnoticed during the clinical trial program. 
The First reason that clinical trials cannot catch all the ADR is small sample size (up to 
1000 patients). This small size reduces the chance of finding rare adverse effects. The 
second reason is limited patient diversity (Homogeneous populations). Most trials use 
healthy patients with only one disease and normally exclude specific groups such as 
pregnant women, children, and elderly people. The only way to make the clinical trials 
helpful in term of detecting and identifying adverse drug reaction is to make the 
medication widely use in a general population and this is impossible because the 
medication is still not certified. The third reason is insufficient periods of follow-up. Due 
to this Limited duration, the trials of short duration cannot detect or discover all the ADR 
specially the long term consequences such as cancer. Once the drug is released and starts to 
be available in the markets, a huge diversity of patients uses the medication. This will 
increase the possibility of previously undetected problems to arise and be identified. For 
example  phocomelia which is due to thalidomide took several years to be identified [14]. 
Additionally, adverse reactions occur at low frequencies that make it difficult to be 
identified in the small numbers of patients as the one in clinical trials. 
The clinical trials cannot predict real life problem that can be resulted from the 
interaction of medications that a patient is taking simultaneously [1] and [3]. This is beside 
the difficulty of predicting how the medications will be used by both physicians and 
patients [16].  
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1.2.3.2 Post-marketing Surveillance 
 
Given the limited information available when the drug is marketed, postmarketing 
study has become increasingly important. Post-marketing surveillance is the process of 
identifying, reporting, and responding to the issues occurred while taking medication [1, 3, 
14, 17]. This method is the principal method used for monitoring the safety of marketed 
drugs nowadays. The responding includes actions that can be taken to improve product 
safety and protect the public health, such as labeling changes, safety alerts or product 
withdrawals [12] and [3]. Even if the report does suggest labeling changes, the information 
provided will be kept for further investigated especially when more information became 
available. Once the reports are studied and evaluated, the data generated can help to 
identifying ADR with certain medications and investigate these ADRs to provide clear 
indicators that can be used to identify other ADR resulted from other medications. To date, 
many methods have been adopted into postmarketing studies, including ADR case review, 
comparative observational study, ADRs Spontaneous Reporting, and Data Mining 
Algorithms. 
ADR Cases Review 
Case review is one of the most often used methods in the initial recognition of 
some possible ADRs signals. Many drug safety concerns were initially initiated by case 
review. For example, A case report in the April 2007 Journal of Laryngology & Otology 
[18] of sudden hearing loss in a man taking sildenafil made the U.S. Food and Drug 
Administration (FDA) search its Adverse Events Reporting System for other similar cases. 
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It found 29 similar cases of sudden hearing loss were reported after the medication had 
been approved and marketed.  Those cases trigger an investigation that make the U.S. Food 
and Drug Administration (FDA) change the label of such mentioning that such medication 
can lead to sudden hearing loss. This will guide patients on what to do if they experience 
such hearing problems with taking that medication. As mentioned in the previous example, 
an initial case report lead to a series of further investigation that can identify an adverse 
event. 
However, with the dramatically increased values of drug safety reports, case review 
will be extremely unacceptable because such manual searching and reviewing process of 
unknown signal pairs is time consuming and easily with that amount of huge data a signal 
pairs can be missed.  
 
Comparative Observational Studies 
Traditional comparative epidemiologic methods, sometime called case-control 
study and cohort study, have been widely used in characterizing the risk and benefit profile 
of medicines. However, they face similar challenges as clinical trials in terms of 
insufficient sample size and the difficulty of detecting rare events that need long time to be 
identified.  
 
ADRs Spontaneous Reporting 
In the United States, most ADRs are reported to the Food and Drug Administration 
by drug manufacturers in early stages. Hospitals and clinics are also required to monitor 
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suspicious adverse drug events and to report them to FDA. Many large ADRs spontaneous 
reporting systems (SRS) have been developed worldwide, which make early detection of 
ADRs signal. To date, the major ADRs SRS available for the public access include the 
Adverse Event Reporting System (AERS) of the U.S. [19], the Yellow Card of the U.K. 
[20],  the Canadian Adverse Drug Reaction Monitoring Programme (CADRMP) of Canada 
[21] and Central Drugs Standard Control Organization of India (CDSCO) [22] and [23]. In 
those systems, Physicians pharmacists and nurses are encouraged to report any reactions 
that can be associated with drug use. This association is based mainly on their beliefs.  
Normally the attention is focused more on new medications and serious ADRs rather than 
old drugs and non-serious or unhurt ADRs. The role for SRS is to continuously monitor all 
drugs used in a variety of conditions and quantities, generate signals of potential drug 
problems, and to identify rare ADRs.  
 
ADRs spontaneous reporting System Example: FDA MedWatch Program 
The most important source of adverse event information to the FDA in U.S. is the 
MedWatch program [4, 24, 25]. In this program, healthcare providers and patients can 
submit an adverse event report via several mechanisms including an online report form, 
phone, fax and mail. The reports are stored in a database, the Adverse Event Reporting 
System (AERS) [12]. Besides those reports AERS database contains adverse events 
reported by the drug manufacturers. The largest source of information about drug safety is 
the drug companies themselves. The AERS database is made publicly available on the 
Internet to clinical reviewers and researchers in order to monitor for drug safety and detect 
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adverse events [12] and [26]. AERS contains approximately around 2.5 million adverse 
event reports [12].  The FDA searches these reports for serious events that can lead to 
death, hospitalization or disability. The study of those reports and the statistical analysis of 
the data available can save patients’ lives and lower hospital admission cases. The reports 
will be used to for signal pairs link generation not testing [17] and [3]. 
MedWatch has been successful at identifying adverse event of medications but it is 
still slow and is characterized by other major limitations [3, 4]. For example the system 
took an average of 5.9 years to detect the toxicity of fifteen medications removed later 
from the market between 1997 and 2005. The Medwatch system do well in identifying 
adverse events in the early stages after administration of medications but it was unable to 
find events that occurred later, during chronic administration, as reported by [17].Since 
Medwatch is using database for report collections and no unique standards for collection of 
data, the database can contain incomplete information that will affect the derived results 
from these information. Detection of signals in Medwatch is limited due to the low 
percentage of adverse events which are rare event (less than 10 percent). The quality of the 
reports and the accuracy of the information written in the reports can also affect the 
detection performance of the adverse events. Some time, for instant, the health providers 
don’t appreciate clinical finding or adverse events until the occurrence became wider in 
patient population. Also we need to remember that MedWatch reporting is voluntary job 
and many suspected adverse events are not reported based on the physicians point of view 
[26] , [12] and [27].  
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Other Spontaneous reporting systems, such as Yellow Card of the U.K, suffer from 
low reporting rates, typically less than 10%. Underreporting of ADRs is a common 
problem in spontaneous surveillance programs which can delay adverse event detection 
and underestimate a problem size. Knowing the factors that may confirm an adverse event 
will assist heath providers and physicians in establishing ways to correct underreporting. 
[28] and [29] provides different reasons that needs to be analyzed in order to improve the 
quality of reporting. There are huge number of reports that are available in the databases 
that make it difficult for physicians who to analyze the reports of adverse reactions since 
they have little time especially most of the reported events  have a low likelihood of a 
causal relation. 
Paper [30] explained other  limitations that affects the spontaneous report systems . 
One of these limitations is biases. Different biases can affect the reporting since the 
spontaneously reported information is uncontrolled and depend heavily on the person who 
files the report. These biases include the report writing environment, quality of available 
data at the time of writing the reports, quality of information submitted in the reports and 
the length of time the medication has been on the market. The adverse event report should 
include the following: Drug name; demographic data; clinical description of adverse event, 
including laboratory test results; confounding factors such as concurrent diseases or other 
medications; temporal information, including date of taking the medications and the date 
of appearance of the symptoms, start and stop dates of the medication; dose of medication; 
dechallenge/rechallenge information (if available); and outcome. Have a high quality 
report is a time consuming process that make physicians or health providers avoid 
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reporting events. A collaborative approach for detecting and reporting adverse events is 
needed in order to catch all suspicious cases [28].  
 
 Data Mining Algorithms  
Pharmacovigilance concern is mainly with the time need to discovery of adverse 
events taking in to the account the clinical nature of the event, and/or the appearance 
frequency of event. With this ever-increasing amount of reporting data there is interest in 
using computer- algorithms to identify the signal pairs. Such techniques are also known as 
data mining algorithms. Data mining algorithms are used to search extremely large 
spontaneous reporting system databases for statistical dependencies between drugs and 
events. Data mining algorithms are relatively new that can provide a fast and efficient way 
of detecting possible ADRs signal.  If data mining algorithms identified a causal 
relationship between taking the medication and appearance of the event due to sufficient 
correlation between the statistical dependencies, the data mining algorithms could improve 
signal pairs detection performance.  
Several data mining algorithms  have been well described in literature, some are 
based on simple analysis, e.g., the reporting odds ratios [31] and the proportional reporting 
ratios [32].  
The reporting odds ratios was first established in the Netherlands 
Pharmacovigilance Centre Lareb [31]. Compared to other data mining algorithms, 
reporting odds ratios is easy to calculate. Like the traditional odds ratio in epidemiology, 
reporting odds ratios is an estimate of incidence rate ratio, calculating the odds of the 
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exposure of suspected medication in those who had adverse events divided by the odds of 
the exposure of suspected medication in those without adverse events. 
The proportional reporting ratios, as another early attempt of quantitative analysis 
of ADRs reports, was first used by Evans and colleagues in 2000 to demonstrate the risk of 
uveitis associated with the use of rifabutin [32]. The proportional reporting ratios measures 
the strength of causal relationship between the suspected drugs and suspected ADRs. The 
proportional reporting ratios behaves in a similar way to the relative risk. The higher the 
value of the proportional reporting ratios is, the stronger the strength of the signal appears 
to be. Screening the ADRs reports based on the values of the estimated PRRs could save 
time and prevent some unnecessary efforts. 
 Other DMAs techniques are available, e.g. Bayesian Confidance Propagation 
Neural Network [33] and Multi-Item Gamma-Poisson Shrinker [34]. 
 
Data Mining Algorithm Example: Bayesian methods 
Bayesian uses the concept of probability as the degree to which a person believes a 
proposition, which is completely opposite to the view of ‘frequency probability’. 
‘Classical’ frequents always assume that the size of a population is unknown but it is fixed. 
The population parameter size can be estimated by selecting a random sample out of the 
population. For example, if we repeat an experiment (e.g., tossing coin) and observe the 
phenomenon (e.g., head or tail) with enough times, it would become clear what the future 
probability of reoccurrence will be (e.g., the probability of getting head or tail will close to 
0.5). However, it is impossible to keep the event generating conditions exactly the same 
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especially when this method is used to obtain a large number of outcomes. For example, in 
tossing coin example, we cannot guarantee that each time the way of tossing the coin is 
exactly same. Another fundamentally different is that a Bayesian method starts the 
inference with pre-existing subjective personal estimation of the unknown parameter and 
the probability distribution (called prior distribution). The subjective assessment can come 
from the previous experience of the person, who run the experiment, or from experts’ 
knowledge, or from some initial assumptions depending on the circumstances of the 
experiment. By providing more information, the ‘degree of belief’ can be updated. 
Basically, the updating of the information in Bayesian approach is based on using the 
Bayes Theorem. 
Data mining algorithms are being used to explore spontaneous reporting databases 
for adverse reaction signal pairs. Paper [5] compares the finding of data mining algorithms 
with those came from classical reporting methods. Most adverse events identified by both 
methods were highlighted in product labeling. Classical reporting methods identified four 
potentially unexpected serious adverse events which may lead to label changing and close 
monitoring. The other finding of that paper that none of these adverse events has been 
identified using the data mining algorithms. This make the data mining algorithms based 
on that paper is not helpful since it could not detect or enhance the classical reporting 
methods surveillance in this particular setting. Data mining algorithms performance may 
be enhanced by selecting the most appropriate pharmacovigilance tools that are designed 
specifically for each situation [35]. Also in [36] five data mining algorithms are used for 
identifying possible adverse drug reactions from spontaneous reports information. The 
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study concludes that the detected drug–ADR signal pairs vary between different 
methodologies and this make the data mining algorithms unreliable.  
The availability of huge amount of reported events, including false-positive signals 
as a result of the existence of confounding will produce unhelpful hypotheses. This may 
affect the capability of data mining algorithms to detect true positive signals of real causal 
associations which will lead to serious consequences that delay the detection of the signal 
pairs. 
Data mining algorithms had not been generally accepted by health providers, 
Physicians or pharmacists. This is due  three main reasons based on [3]: 
1. The apparent complexity of its mathematics and the hidden strategy of detecting 
the signal pairs deters those unfamiliar with statistics. 
2. Even with increasing availability of epidemiological and 
pharmacoepidemiological databases, background information for calculating prior 
probabilities is still either unclear or unavailable. 
3. The pre-marketing data from clinical trials is usually not available for the public in 
order to be used for estimating the prior probability because it has been kept 
confidential between the drug companies and regulatory authorities. Even when 
they are available, they may not be in a format that is suitable for Bayesian 
methods.  
Since no consensus exists regarding the use of data mining algorithms, the use of 
such methods in pharmacovigilance is still limited and not embraced by health providers 
even those methods may draw attention to more “surprising” drug–event signal pairs. In 
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fact, the unknown features of the data (i.e., the event background incidences) and the 
underreporting problem of the events from health providers to the regulatory authorities 
will have direct effect the outcome of data mining algorithms [37]. 
 
1.3 Multi-Agent System Technology Overview  
 
"An agent is the fundamental actor in a domain. It combines one or more service 
capabilities into a unified and integrated execution model which can include access to 
external software, human users and communication facilities" [38]. 
 
 
1.3.1 Introduction To Multi-Agent Systems 
 
Multi-agent system has been a hot topic in recent years. And it’s still be researched 
and developed because it will have an important effect once it comes to our life. Multi-
agent system methodology offers an implementation that fits the design needs. The agent is 
a special software working for its human client/clients to perform certain tasks that imitate 
human agents or systems and it has the ability to be autonomous in its action. From that 
definition we can conclude that an agent is autonomous because it has control over its 
actions and it pursuit them without direct involvement of its human agent or others. The 
agent is also social because it can cooperates and communicate with other agents and 
hence their humans in order to complete the required task. An agent is reactive since it is 
conscious about the updating of available data and changes in circumstances and responds 
based on in that in a timely manner.  This entire make the agent rational in achieving its 
goals. 
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Although the agent can be based on a single agent working just with its human and 
is trying to perform his task, it is normally found in an environment that consists of 
multiple agents that not necessarily sharing the same interest. Agents work with each other 
in a cooperative way to complete certain task that cannot be done with single agent. The 
agent can interact with each other directly through communication (benefit sharing) or 
indirectly by providing certain information either to its users or clients which will require 
immediate actions from other agents in the same environment. Agents decide to work with 
each other either to complete its own task (or interest) or for mutual benefits to serve the 
entire environment (or complete a common goal). A set of agents that help one another in 
solving problems by using cooperation, coordination and negotiation techniques is called a 
multi-agent system.[39]. 
Multi-Agent system is also called Distributed Artificial Intelligence since the 
agents are normally distributed across different locations and collaborate through different 
network hosts. The system is considered distributed if several units (not necessary agents) 
are engaged in carrying out a task and it is opposite to the centralized system where a 
single unit in certain location is carrying out all the parts of a task and no need to interact 
with other units.  
The multi-agent system is a complex system in both its structure and its 
collaborative functionality. Agents must be supported with interaction strategies that make 
them capable to select the appropriate activity at the appropriate time [40]. Agent learning 
focuses on learning how to communicate with other agent, learning how to coordinate 
different activities, learning how to manage a given task until completion, and learning 
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from other agents.  If the agent is learning from other agent available in its environment, 
the learning is considered cooperative leaning while if the agent is learning only from its 
self through expertise and observations, the leaning is considered individual learning.   
Multi-agent systems have been widely adopted in many application domains 
because of its offered advantages  [41]. Some of the benefits of using multi-agent system 
technology in large systems are: 
1. The complex task may be divided to different part and each part can be handled 
concurrently by specific agent. Different tasks or services can be distributed among 
the agents based on their complexity so each agent will deal with certain number of 
task rather than dealing with all tasks.  
2. The speed of performing a task will be increased due to parallel computation and 
asynchronous operation.  
3. The multi-agent system is more reliable than the centralized system because the 
multi-agent system is a distributed system than doesn’t rely on a single unit in 
doing a required task. If a failure takes place in a unit in a multi-agent system, the 
rest of the agents continue doing the task. 
4. The multi agent system is a scalable system since agents can be dynamically join 
or leave a team according to their availability and based on the need required to 
complete a task.    
5. The Computational and communication costs associated with multi agent system 
are much less than centralized systems. Dividing agents in different team will 
reduce the communication traffic and hence the cost. 
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Agent talk with each other using special communication language called agent 
communication language (ACL). This language relies on speech act theory [39]. An ACL 
support the agents with a variety of resources needed for exchanging information and 
knowledge. 
The Knowledge Query and Manipulation Language (KQML) was the first agent 
communication language. Nowadays FIPA–ACL (Foundation for Intelligent Physical 
Agents - Agent Communication Language) is the most usable agent communication 
language and it uses almost all the aspect of KQML [42]. FIPA_ACL incorporates a lot of 
predefined interaction protocols that manage conversations between agents. The primary 
feature of FIPA-ACL is its compatibility since it allows the use of different content 
languages. The FIPA model provides an open architecture that allows the agents to be 
added or removed easily from a team not like other agent communication languages 
models that have closed architectures where the iterations are fixed.   
 FIPA-ACL has 22 performative (or communicative acts) that specify the excepted 
flow of messages (either sent or received) from agents, and type of messages (inform, 
request, propose, failure, confirm, disconfirm, agree, accept, propose, cancel, refuse, query, 
etc.). FIPA-ACL makes sure that the sent message will be understood in the same way the 
sender needs [38] .  
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1.3.2 Applications of Multi Agent Systems  
 
Multi agent systems (MAS) have received considerable attention from researcher 
from different fields in recent years. The Research of multi agent system involves applying 
this technology in different files, investigating the best way to make the agents interact 
with each other and the focus is mainly on information retrieval and management, 
developing the existing agent tools and software to make the simulation better, and  
analyzing the autonomous behavior of agent. In this next two sub section, I will mention 
some MAS applications. 
 
1.3.2.1 Applications in Healthcare 
 
Multi agent system has been used in heath care domain to solve different kinds of 
problems. In this section I will motion a set of examples where this technology has been 
applied.  
 Patient scheduling: In [43], the researcher proposed a multi-agent system to 
schedule different medical activities (tasks required by physicians) that is required to 
be done from a patient in a hospital. 
 
 Organ transplant management: coordinating the management of organ and tissue 
transplants among different medical centers is another application of multi agent 
system in health care domain [44] , [45] and [46].  In [44] the paper proposed a 
Multi-Agent architecture to coordinate the Spanish activity in organ transplants. The 
proposed architecture maintains the current Spanish health organizational structures 
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and then employs different agents that keep up to date the history of the transplant 
and the procedures followed. The proposed architecture has two agents. The first one 
is Emergency coordinator Agent which holds information about patients who need an 
organ and their clinical condition are severe. The other agent is Historical Agent 
which has all the history of organ transplant in Spain. Such data can be used for 
future studies and analyses.  The architecture presented in this paper focuses on the 
organ transplant coordination task. The basic ideal of the proposed system is that one 
agent gathers the information of patients who are waiting for organ so when the 
matching organ becomes available the agent will provide the detail and locations of 
the organ. The researcher found that the proposed architecture accelerate accelerates 
of the organ transplant process in Spain.  
 
 Community care: Multi-agent system has been used in coordinating all the activities 
that have to be performed in order to provide an efficient health care to the citizens of 
a community (especially older or disabled person, [47] ). Paper [48] presented an 
architecture that uses multi- agent system technology to assist health care providers at 
rural areas especially when a specialist is not available, for example, a nurse is trying 
to diagnose a case in the absence of a specialist. The proposed system has an agent 
that contains some knowledge about certain diseases including symptoms and the 
required procedure to be followed. According to the authors of the paper this system 
will provide the health providers in rural areas with expert opinions (already stored in 
the system from specialist doctors). 
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 Information access: Multi-agent system is used to gather information from the 
agents distributed in different location, i.e. agents monitor patients and the system 
may deploy that gathered information to the corresponding units or person (example 
physicians) in order to follow up medical care of the cases. Multi agent system has 
been used to provide the user (patients) with a variety of information about available 
medical clinics/centers, physicians, and other medical facilities like laboratory 
centers or medical imagining centers in a particular town [49]. Such services will 
help patients and save their time. 
 
 Decision aid systems: Multi-agent has been used to monitor the clinical condition of 
patients in hospital and at the same time help in diagnosing the disease [50]. Multi 
agent system has also been used in reduce unnecessarily visits to general practitioners 
especially those who suffer from lifelong diseases (for example diabetes and high 
blood pressure) and they need continues monitoring. For example paper [51] Shows a 
multi-agent system that has a doctor agent that will monitor the status of a diabetic 
person. Each time a sugar test is taken, the result will be analyzed by a physician 
agent using fuzzy inference system that has access to patients’ information and 
history. If the result is abnormal, then the multi agent system will notify the general 
practitioner of the patient. This may lead to a clinic visit to make sure everything is 
going fine with the patients. In this paper they are dealing with fixed well known 
rules for diabetes.  No agent learning was presented in this paper. 
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 Internal hospital tasks: Multi-agent system is used for continuously monitoring 
medical protocols in hospitals [52]. In the proposed system, the agents understand the 
medical protocols in hospitals and then supervise the usage of them. The agents will 
warn the practitioners about forbidden procedure and unlawful decisions. Multi-agent 
system is also used  for controlling and mentoring  the usage of restricted antibiotics 
that can affect patients life [53]. 
 
 Tutoring System for Nurse Education:  Paper [54]  describes a system that can be 
used for nurse education. The system provides intelligent tutoring agent called “Ines” 
that trains the nurses through asking questions and examples (pre defined in the 
system) and guides the nurse students step by step to understand a topic. The authors 
claimed that this system provides the nurses with more practical experience and 
exercises due to lack of facilities, materials and time (given to nurses by instructors 
or trainers) during their study at school. Such system provide a teaching environment 
that support nurse education. 
 
 
1.3.3.2 Other Fields of Applications  
 
Intelligent agents have already been proposed to deal with many different kinds of 
problems other than health care problems. Here is a short list of examples that shows some 
fields in which multi agent systems have been applied. 
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Paper [55] proposed a collaborative multi agent architecture for e- commerce 
application. This paper specifically focuses on travel industry. In that system travel 
agencies provide Individual customers with the flight, hotel and car reservation based on 
three agents: flight agent, hotel agent and car agent. 
Paper [56] proposed a system that consists of  travel agent that helps in reserving 
flights in travel industry. All flights data is stored in a single database. When the customer 
wants to make a reservation for a trip at certain time, the trip information will be passed to 
a flight agent. The flight agent will use the stored flight data to check if the flight is 
available or not. If it is available a reservation will be made otherwise the customer will be 
notified with impossible to fulfill the reservation in the selected dates.  
Paper [57] was an attempt to solve the problems of personalized information search  
through web [58] in a simple way. They proposed one agent, Personalized Search Agent 
(PSA), that allows the user to specify a specific domain in order to perform the search in, 
and then browse the retrieved information in that interested domain. The personalized 
Search Agent is supported with learning mechanism that allows the agent to learn some 
user profile parameters that will enhance the retrieved results in future search. The learning 
mechanism is based on user feedbacks. This adaptive tool makes PSA more powerful and 
effective with use.  
 In [59], the implementation of multi-agent based Radio frequency identification 
(RFID) middleware for asset management application was described. Each assist in 
universities, hospitals or government departments has a bar code that can be scanned to 
record the status of the assets (especially valuable assists). This is done usually with a bar 
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code reader which requires line of sight (the reader is facing the asset directly) with the 
assets in order to be scanned. Otherwise the scan process will fail. In this paper they 
proposed to use RFID technology to monitor valuable assets. This technology doesn’t 
required line of sight with assets. It just requires the item to be in the area of scanner. This 
will allows automatic scanning in the absence of human user. Each item will have a unique 
number placed in a tag that is readable by REIF reader. In this paper they proposed RFID 
middleware which is the tool that helps to make sense of the RFID tag data. It translates 
the simple read data into useful information that can be forwarded later to the interested 
person or unit. The proposed multi agent system consists of three agents. The first agent is 
Client Application Agent which is just responsible for taking the order of checking the 
assets from the human user through graphical user interface.  It passes the request to the 
second agent, the Event Generator Event, which will check if the requesting assist is 
available and it is known by the system. If the name is not registered and not known, it will 
notify the Client Application Agent otherwise it will contact the third agent; the Reader 
Agent. The reader agent has a direct contact with the physical reader who is responsible for 
scanning the items and provides the required details back to the Event Generator Agent 
which will forward it again to Client Application Agent and hence his user. 
Paper [60] discusses using multi-agent system technology for an intelligent 
environment application. They propose to use multi agent system to remote monitoring an 
environment through different sensors distributed at different locations. The proposed 
MAS consists of four intelligent components namely accumulative personal preferences 
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learning, intelligent resources allocation, reactive controls and context-aware proactive 
controls.  
Paper [61] explored the problems that are facing mobile companies and the used 
technologies. They expected that multi agent system can enhance services provided to the 
users and provide real time fraud detection in mobile phone networks. They claimed that 
the multi agent system can customize the services provided to clients. They propose a 
multi agent system that consists of   Personal Communication Agents, Mobility Network 
Agents, and of Fraud Breaking Agents. 
Papers [62] and [63] show another application of multi agent system which is the 
application of E- learning and E- teaching. Paper [62] proposed an agent-based Intelligent 
Tutoring System for e-learning/e-teaching. The proposed system consists of four agents 
Preferences Agent, Accounting Agent, Exercises Agent and Tests Agent. The multi-agent 
system provides an environment that enhances the educational system by providing the 
students with different exercise, materials, and exams. At the same time the performance of 
the students will be monitored and based on their progress new tasks can be provided. The 
teachers have access to the system to consult the students. Teachers can change the level of 
exercises or provide additional materials to support the learning progress and to improve 
student motivation. The system can provide the teachers with different statistics that will 
enhance the educational system.   
Multi agent system has been used in power Engineering applications such as [64] 
and [65]. Paper [65] presents possible benefits that can be gained by using multi-agent 
technology in power engineering industry. The paper included different concepts of agent 
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system that are appropriate to power engineering field. It also presented a review of 
important power applications that will be enhanced by multi-agent systems.  
 
1.4 Original Contributions  
 
My contributions are as follows: 
 
     I developed a multi Agent system for identifying adverse drug reaction signal pairs 
as early as possible [66, 67].  The developed multi-agents system provides Physician 
Assistant Agents that are capable of collaborating with one another, sharing patients’ 
information and exchanging knowledge. This collaborative system will accelerate the 
process of detecting ADR signal pairs comparing to the existing system which relay 
on spontaneous report which suffer from underreporting and other limitations as 
explained in section 1.2.  The developed system can also be used in the early stages 
of medication testing, i.e. clinical trials, because any case presented to any agent or 
any decision rule added to the agent brain can be shared with other PAA not as in 
existing system where a physician or a drug manufacturing company wait until there 
are sufficient suspicious cases in order to report the potential adverse event.   This is 
very important issue in identifying ADR signal pairs because the adverse event 
appears normally in a population at very low percentages.   Each agent in the 
developed system is equipped with a decision engine, which enables it to find the 
causal relationship between a drug and a potential ADR (i.e., a signal pair).The used 
reasoning is based on fuzzy logic involving fuzzy rules and fuzzy reasoning 
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implemented using the freeware FuzzyJess [7]. Integrating a decision mechanism 
into agents make them more proactive and encourage closer agent-human 
collaboration [39] and [68] . The developed system allows the agents to use different 
databases available in health organizations systems in the process of identifying the 
adverse drug reaction signal pairs. Such databases weren’t used before in the 
literature to identify signals pairs. All the existing methods are depending mainly on 
spontaneous reports reported by physician. 
 
 I developed a methodology that allows the agents  in the developed multi-agent 
system to find similar patients [69]. The developed methodology enables the agents 
to interact effectively with each other by setting up an environment that allows 
learning and working in a proactive way. This methodology can also be generally 
used to address other similarity problems in different field of multi-agent systems. To 
the best of our knowledge, no work has been reported in the literature to address 
these issues. Finding similar patients in a multi-agent environment is a complicated 
problem. This is the case if we realistically assume that there does not exist a set of 
similarity-finding rules that are readily acceptable to all the users of the agents (i.e., 
physicians) because “similar” is really a vague, subjective measure rather than an 
objective measure. Furthermore, the specifications of the similarity-finding rules vary 
among the agents because agents formulate their similarity rules according to their 
human users’ experience. This will make it difficult among the agents to decide 
which physician id right or wrong. It should be obvious that these dynamic issues 
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will pose challenges when the agents work collectively to help one another to reach a 
common goal (e.g., ADR detection). Patient similarity is characterized by a number 
of factors related to physician's experience. I developed similarity rules that are used 
by PAAs to find similar patients. The  developed  rules is based on temporal 
association of a medication of interest, abnormality of a laboratory test, age, 
medications, and Symptoms and morbidities(chronic and acute). There are a total of 
38 similarity rules.  
 
  I equipped the agents in the developed system with a fuzzy inference engine in order 
to be able to find causal relationship between a drug and an adverse reaction. The 
parameters used in identifying the signal pairs are really a vague, subjective measure 
rather than an objective measure. Up to our knowledge, no set of rules was clearly 
mentioned in the literature that took advantage of this vagueness. Furthermore, 
physicians often disagree one another owing to their knowledge and experience levels 
and usually there is no “ground truth” to indicate which physician is right or wrong.  
The developed fuzzy inference engine also uses the distributed databases available for 
the agents in the multi- agent system.  Such databases have not been used before in the 
literature for such purposes. Databases in current systems are mainly used a for 
knowing the medical history of patients by only their physicians, improving the 
quality of provided services and reducing the costs of medical errors. These databases 
provides valuable information about patients including age, sex, medication took by 
the patients, symptoms appears on patients, Laboratory tests results, and procedure 
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followed by the physician at the visit time. The proposed ADR signal pairs detection 
methodology is based on five cues: temporal association, rechallenge, dechallenge, 
abnormality in laboratory tests and other explanation. The cues represent the higher-
level information that is obtained from the patients’ elementary data. The detection 
rules that use the above cues were acquired through the joint efforts of the engineering 
and medical team members. There are a total of 52 fuzzy detection rules. 
 
  I have developed a new learning mechanism that allows PAAs in the multi-agent 
system to effectively learn from each other through exchanging detection and 
similarity rules. The problem of learning in multi-agent system is an essential 
problem. All the existence methods deal with multi-agent system in certain aspect 
where a task will be divided among different agents who have different roles. Then, 
each agent will complete his part of the task based on the pre-defined rules. Finally, 
different parts of the job will be collected and the task will be considered done. Other 
studies uses different agent with same role (like players in a game) to perform a task 
(win the game) and if a decision need to be made it will be based on majority vote.  
Usually, agents formulate their rules according to their human users’ experience. For 
an individual agent, if these experience-dependent rules are incomplete, it could 
cause inaccurate determination of required task especially in new issues where the 
rules still not clears and finalized. In addition, we assume realistically that we do not 
know which rules are right or wrong. Furthermore, the numbers of patients seen by 
different physicians (and hence their agents) are different. This will affect physicians’ 
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experience levels as well as the numbers of rules their agents should have. More and 
better rules should be used as the physician sees more and more patients. This fact 
should be reflected in the agent system behavior. This make me developed learning 
mechanize that is based on confidence level approach. This learning mechanism can 
be used in other applications of multi agent system.  Each detection or similarity rule 
has been assigned a confidence level. The confidence level reflects the experience of 
the agent in that rule. In other words, the confidence level tells how certain the PAA 
is about the rule. The rules that have been used have higher confidence levels than 
those that have not been used. Having confidence levels for the rules allows agents to 
benefit from each other in a cooperative way. This allows the most important and 
insightful detection rules to be found and used for the benefit of the entire agent 
system. The new updated rules will lead to improve the agents’ decision 
performance. 
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1.5 Organization of the Dissertation 
 
 
The rest of this dissertation is organized as follows. Chapter 2 presents the 
design and architecture of a multi agent intelligent system for detecting adverse drug 
reactions. Chapter 3 describes the methodology used for Finding Similar Patients in 
Multi Agent Environment. It includes the details of the experiment used to validate the 
used methodology.  Chapter 4 illustrates the approach of identifying Adverse Drug 
Reaction Signal Pairs by a Multi-Agent Intelligent System. Chapter 4 also includes the 
experiment used to validate the used multi-agent approach for identifying the signal 
pairs. Finally, Chapter 5 concludes this dissertation and provides the future directions. 
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CHAPTER 2 
DESIGN AND ARCHITECTURE OF A MULTI-AGENT 
INTELLIGENT SYSTEM FOR DETECTING ADVERSE 
DRUG REACTIONS 
 
2.1 Collaborative Multi-Agent System Architecture 
 
 
Figure 1 depicts the general organization of my multi-agent system for ADR 
detection that previously proposed [67, 70]. The FDA is at the top of this structure since it 
is the drug administration authority in the United States. Many health organizations are 
connected to the FDA. Experts in the FDA and physicians in the local health organizations 
have their own intelligent agents. The National Regulatory Authority Agent has the highest 
authority and carries out necessary management and information collection tasks. The 
Safety Evaluator Assistant Agents help the safety evaluators in the regulatory authority 
(e.g., FDA) make decisions. The Pharmacist Assistant Agents and the Epidemiologist 
Assistant Agents utilize the expertise of pharmacists and epidemiologists respectively and 
collaborate with the Safety Evaluator Assistant Agents in supporting safety evaluator's 
decision making. The Health Organization Agent is a broker and controller for each health 
organization. Within each health organization, there would be a unique Health 
Organization Agent and many PAAs. Physician Assistant Agent (PAA) helps a physician 
acquire useful information and make decisions. PAA can communicate with other PAAs in 
the same or different health organizations. The physician Assistant agents’ skill levels are 
not the same. The solution of a problem involves the coordination of the effort of different 
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agents with different skills and functions. PAAs will react to changes in their environment 
in a proactive, autonomous and intelligent manner. Each PAA will perform tasks that may 
be beneficial for the physician.   
 
 
Figure 1.  The multi-agent system architecture for ADR detection. 
 
To illustrate the ADR signal-pair detection process, I will focus on PAA only in 
this study. The PAAs are in the forefront to assist physicians. This is because physicians 
play an important role in the detection of adverse drug reaction since they are the ones 
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who deal with patients who suffer from an adverse event. There are many PAAs located 
in the same or different health organizations. 
A PAA would help the physician request the details of a particular suspected 
patient case and/or similar patient cases from other agents in the same or different 
health organizations. The PAA will perform according its knowledge. The PAA could 
also ask other agents about the rules they are using in evaluating certain ADR cases so 
that the agent can updates rules. The agent can collect similar cases distributed across 
all the healthcare systems. The PAA could also track the further development of the 
suspected patient cases under the help of other PAAs in the system. For example, the 
PAA may be interested in what happens if the suspected drug is discontinued. With 
more information, the PAA could more easily determine the causal relationship 
between a new ADR and a specific drug. Once a physician finds potential adverse 
effects on his/her patient, he/she can, with the help of his/her agent, search more 
information or simply file a report to the safety officer or safety evaluator, which will 
trigger the surveillance process for the particular drug.   
The PAA will keep all the cases seen by its physician in his records and update 
them when new information is being available. Next time if any other physician 
receives such similar case, the agent can automatically inform him/her with that similar 
case. Finally, the PAA can decide to take any of the following actions depending on the 
decision reached, i.e.: 
 To order some extra clinical tests. 
 To continue the same medical treatment or to modify it. 
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 To schedule another visit for the future. 
 To transfer the patient, for example, hospitalize him if his health has deteriorated too 
much. Patients can also be transferred from one of the health centers to another 
according to the patient needs. 
 
In the context of this research, a PAA would help the physician retrieve the details 
of a particular patient case and request similar patient cases. The PAA will provide its 
physician with the similarity score for each similar patient. The PAAs will also work with 
each other in order to detect potential ADR signal pairs (i.e., potential links between drugs 
and apparent adverse reactions). 
 The detection process starts when an agent sends its request to the rest of the 
agents to help in a certain suspect case. As a first step the agents will collaboratively work 
together in a way that the more experienced agents will help the less experienced agents. 
The agents will start collaboration by providing their detection rules to the other agents. 
This will allow the most important and insightful detection rules produced by the most 
experienced agent (defined in this study as the agent that has the largest amount of patients 
in its patient database) to bubble up for the benefit of the entire agent community. The 
updated rules will lead to improved detection performance. After finishing the learning 
process, the agents will retrieve patient cases one by one from their databases in order to 
evaluate their own cases using the new learned/updated rules. Having ample similar cases 
will provide the requesting agent with more evidences about the suspect case and thus 
helps in decision making. The other agents will forward the similar cases along with their 
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signal pair strength to the requesting agent.  The agents will keep all the cases seen by 
their physicians in their records and update the decision when new information becomes 
available. The proposed multi-agents system would assist physicians in hospitals and 
clinics, accelerating the process of identifying ADR signal pairs by assuring that the 
relevant information and knowledge distributed across different locations can be utilized 
more expediently.  
 
2.2 Design of PAA-Based Multi-Agent System  
 
Figure 2 shows PAA-based multi-agent system that I developed for detecting ADR 
signal pairs. (n PAAs are shown). Each PAA has its own patient database that contains the 
records of the patients already seen by its physician. Each PAA is equipped with a certain 
number of detection and similarity rules. . The rules used in the experimental part were 
acquired from the physicians on the team through the joint efforts of the engineering and 
medical team members after a careful analysis of the relevant literature. White Board 
provides the ability for a PAA to communicate with other PAAs without prior knowledge 
about them. It contains information about agent service type, agent name, communication 
languages and ontologies. This information allows White Board to connect different agents 
located at different health organizations. An agent can use White Board to search for other 
agents that can provide services to aid it in fulfilling its particular goals. To do that, White 
Board will provide requesting agent with the name of other agents based on the nature of 
the request. White Board collects similarity rules and confidence levels from PAAs in 
order for them to be used in the rule updating process described later. 
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White Board contains Shared Data and Notification Unit which is responsible for 
storing important data about certain cases that matches some special criteria and the 
location of these cases. The Shared Data and Notification Unit will notify the unavailable 
agents of the appearance of such information when it becomes available or/and if a 
modification was made to certain decision. This will assure the reception of information in 
all circumstances. 
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Figure 2.  Architecture of the PAA showing the four components. 
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Below is a scenario illustrating how three PAAs work together to find similar 
patients using White Board. The same strategy can be applied for identifying signal pairs. 
PAA1 needs to find patients similar to a particular patient case.  It will send a request to 
the White Board asking for other PAAs available in the system that can help in finding 
similar patients. The White Board then turns to its agents. The White Board will make a 
list of agents that are capable of helping PAA1. The White Board knows them from their 
services type (skills). If the list is empty, the White Board will reply with the message 
“impossible to do” to indicate it cannot find any agent in the system to help. Otherwise, it 
iteratively sends ”acknowledgment of acceptance” to PAA1. Suppose that the White Board 
replies to PAA1 and indicates that PAA2 and PAA3 are available. The White Board will 
also provide PAA1 with the addresses of PAA2 and PAA3 so that the three agents can 
directly communicate one another. 
Then, PAA1 sends separate requests to PAA2 and PAA3, asking to communicate 
with them. PAA2 and PAA3 will response to PAA1 and inform it either “agree to do” or 
“reject to do,” depending on whether they are busy or not with other agents. Let’s assume 
that just PAA2 is not busy and agree to work with PAA1 and PAA3 is busy and is not 
available to help.  PAA1 will send another request to PAA2 and PAA3, providing them 
with the patient information. PAA2 and PAA3 will search their patient databases and 
evaluate their patients and assign a similarity score. Figure 3 shows White Board 
interaction methodology applied to the previous example. 
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Figure 3. White Board interaction methodology. 
 
Functionally speaking, the PAA’s architecture consists of five components - 
Communicator and Manager, Similar Patient Finder, ADR Signal Pairs Detector, Rule and 
Confidence Level Updater, and Databases and Database Wrapper. 
 
2.2.1 Communicator and Manager 
 
Communicator and Manager deals with inter-agent communication and manages all 
incoming and outgoing message.  It is responsible for sending requests to Similar Patient 
Finder to start the process of finding similar patients to a reference patient. When Similar 
Patient Finder Finishes the similarity finding process, Communicator and Manager 
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receives similar patients and sends them out to other PAAs.  Communicator and Manager 
is also responsible for sending requests to ADR Signal Pairs Detector to start the process of 
Identifying Adverse Drug Reaction Signal Pairs (i.e., potential links between drugs and 
apparent adverse reactions). When ADR Signal Pairs Detector Finishes the identifying 
process, Communicator and Manager receives suspicious cases and strength of potential 
link in order to be shared with other PAA and/or its physician. The last task of 
Communicator and Manager is sending requests to Rule and Confidence Level Updater to 
update knowledge of Similar Patient Finder and ADR Signal Pairs Detector.  
To find similar patients to a reference patient case which is either received from 
another agent needing similar patients or presented to the PAA by its physician, 
Communicator and Manager will send the received reference case to Fuzzy Inference 
Engine in Similar Patient Finder. Fuzzy sets and fuzzy logic are used to handle vague and 
subjective information in the patient data and physician's knowledge and experience. 
Fuzzy Inference Engine uses Similarity Rules and fuzzy sets to find output variables that 
will be used to find similarity factors between the reference case and a local patient being 
compared with. The retrieved similar patients and their similarity scores are forwarded to 
Communicator and Manager in order to be sent out to the requesting agent and/or its 
physician.   Having similar cases will provide the requesting agent with more evidences 
about the suspect case and thus helps in decision making. When a suspect case is 
identified, the PAA will check whether it is completely unknown or similar to an already 
known case. If it is unknown and no similar case was found, a solution must be generated 
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from scratch. If there is some similarity to a previously seen case, the previous decision 
can be used as a starting point for solving the new one or even to make a decision  
To start the process of Identifying Adverse Drug Reaction Signal Pairs, 
Communicator and Manager sends a request to ADR Signal Pairs Detector. The request is 
either received from another agent needs to identify a signal pair or from the PAA by its 
physician, Communicator and Manager will send the suspect pair to Fuzzy Inference 
Engine in ADR Signal Pairs Detector. Fuzzy Inference Engine uses detection Rules and 
fuzzy sets to find output variables that will be used to find ADR cues. Local patient cases 
will be evaluated and the likelihood that a drug causes a suspect ADR will be determined. 
The strength of this assessment is called Degree of Causality. When ADR Signal Pairs 
Detector Finishes the identifying process, Communicator and Manager receives suspicious 
cases and their “Degree of Causality” scores in order to be sent out to the requesting agent 
and/or its physician.    
The other task of Communicator and Manager is sending requests to Rule and 
Confidence Level Updater to update knowledge of Similar Patient Finder. The updating 
occurs at programmed times. In this project I let the updating to be done once a day at 
12:00 am. In this updating process each PAA will contribute by providing its similarity 
rules or /and Detection rules, and the corresponding fuzzy sets and parameters of formulas 
to White Board. Rule and Confidence Level Updater will use the collected rules in White 
Board to update its own rules and modify the rules confidence levels. This is done by 
selecting the rules that have the highest confidence level. The confidence level present how 
much the agent is sure about a rule. This will allow the most important and insightful rules 
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produced by the most experienced agent (defined in this study as the agent that has the 
largest amount of patients in its patient database) to bubble up for the benefit of the entire 
agent community.  Rule and Confidence Level Updater will also update the associated 
fuzzy sets, and parameters of the similarity formulas in Computing Unit.  The updated 
rules will lead to improved decision performance. 
 
2.2.2 Databases and Database Wrapper 
 
Databases and Database Wrapper contains a Patient Database, an ICD-9 Codes 
Database, and a Clinical Classification Database. Database Wrapper provides two 
important functions: a) it provides frequently-used methods for database connectivity. It 
provides a simple layer that can deal with standard database language (e.g., SQL). Java 
Database Connectivity (JDBC) wrapper library was used in my dissertation, and b) it 
offers a wrapper that maps the human description of a case to different medical codes 
(ICD-9, Clinical Classification, etc.) that are commonly used in U.S and it also provides 
the opposite mapping. Such codes describe the medical conditions of patients, symptoms 
phenomenon and the procedures followed by physician in order to diagnose a case.  
 
2.2.3 Lexical Processing Unit 
 
The agents are supported with ability of mapping free text terms to unique 
concepts. This was done by this unit. It uses the Lexical Variants Generator (LVG) 
program provided by the National Library of Medicine [71]. LVG is the most powerful 
solution for lexical variations at the individual word level. This unit will allows the agents 
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to deal with inflectional variants, spelling variants, acronyms and abbreviations, 
expansions, derivational variants, synonyms as well as combinations of these. For example 
the agent will deal the following spelling variant words lab, laboratory, labs, laboratory 
(with spilling mistake) as laboratory term.  
 
 2.2.4 Lexical Knowledge Base 
 
This Lexical knowledge base consists of linguistic knowledge, such as synonyms 
of medical words, grammatical patterns in which they can appear, possible abbreviation of 
the medical words and complex medical terminology.  
 
2.2.5  Similar Patient Finder 
 
 
2.2.5.1 Input and Output Variables and Fuzzy Sets  
 
Patient similarity is characterized by a number of factors related to physician's 
experience. Finding the similarity between a reference patient and compared patients in the 
local databases is based on temporal association of a medication of interest, abnormality of 
a laboratory test, age, medications, and morbidities. Temporal association describes the 
relationship between taking a drug and appearance of symptom.  
Abnormality of a laboratory test shows the degree of elevation of a laboratory test 
result. The abnormality will be calculated for Transaminases (AST, ALT), Creatine Kinase 
(CK), Potassium, and Creatinine, which are common tests .Age is another important factor 
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in finding the similarity.  The side effect risk of a medication in a healthy adult is not that 
danger as in elderly patients.  
Medication factor shows the overall view of medications took by the patients 
including medication name, class and quantity. The morbidities factor present all the 
symptoms appear on a patient and have been verified by his physician. The symptoms are 
recorded at the time of physician visit as ICD-9 codes.  
For Each factor input and output variables will be defined in order to be used by the 
Fuzzy Inference Engine, and each variable is fuzzified by input fuzzy sets.  
The fuzzy sets used in fuzzifying the Input and Output variables are shown in  
Table 1. Triangular and bell fuzzy sets are specified by three parameters a, b and c 
while the gaussian fuzzy set is specified by two parameters a and b. 
 
Table 1.Definitions of Fuzzy Sets 
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2.2.5.2 Fuzzy Similarity Rules 
 
Similar Patient Finder is equipped with the similarity rules that link the input 
variables to the output variables using If-Then rules with a condition and a conclusion. The 
initial similarity rules and formulas are provided to the PAA by its physician based on 
his/her experience. Different experience will lead to different similarity finding rules.  In 
this research, the similarity rules are provided by the physicians on the team. There are a 
total of 38 rules developed by the physicians and is used by the four PAAs implanted in 
this project. The rules are distributed among the PAAs to imitate real life problem where 
each physician has his own rules based on his experience. As a result, each PAA will have 
part of the rules to emulate different levels of experiences of the physician users of the 
agents.  
The first step in allowing the agents to benefit from each other is to find a strategy 
to represent the experience of the agents for each rule. In this dissertation, I proposed 
assigning a confidence level, a value in [0, 1], to each rule based on the experience of the 
agent in that rule. The confidence level tells how much the PAAs are sure about its rules.  
In general, to assign a confidence level for a given patient record set to the rule, the 
confidence level is defined as the fraction of the patient records in the set that will fire the 
rule. In other words, how many times the PAA has used that rule. Sometimes the PAA has 
not used all the rules in its Similar Patient Finder. The rules that have been used have 
higher confidence levels than those that have not been used. Each time a new case is 
presented to a PAA in order to be evaluated, Rule and Confidence Level Updater updates 
the confidence levels of the used rules and if the physician input a new rule, it will be 
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added to its PAA rules. PAA will get new rules or/and update rules confidence levels 
through communicating with other PAA. The confidence levels affect the contribution of 
the rules which consequently affects the calculation of the total similarity between a 
reference patient and the compared patients. The inferred output of each rule is scaled by 
the confidence level value via algebraic product before aggregating the output of individual 
rules.  
 
2.2.5.3 Fuzzy Inference Engine and Defuzzifier 
 
A reference patient case is evaluated by Fuzzy Inference Engine using the 
similarity rules to find similar patient cases stored in the local Patient Database. Fuzzy 
Inference Engine evaluates the rules using the min-max fuzzy inference operations. Fuzzy 
Inference System follows Mamdani fuzzy model. The resulting aggregated fuzzy set is 
converted to numerical values for the output variables by Defuzzifier that uses the center of 
gravity scheme.  
 
2.2.5.4 Similarity Computing Unit 
 
   Similarity Computing Unit contains formulas that are used in Similar Patient 
Finder to get the total similarity score between a reference patient and compared patients. 
It contains Similarity Formulas of the resulted defuzzified output resulted from Fuzzy 
Inference System, Morbidities Similarity Formula, Medication Similarity Formulas and 
Total Similarity Formula. The retrieved similar patients and their similarity scores are 
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forwarded to Communicator and Manager in order to be sent out to the requesting agent 
and/or its physician.    
 
2.2.6  ADR Signal Pairs Detector 
 
2.2.6.1 Input and Output Variables and Fuzzy Sets  
 
ADR signal pairs detection methodology is based on five cues: temporal 
association, rechallenge, dechallenge, abnormality in laboratory tests and other 
explanation. The cues represent the higher-level information that is obtained from the 
patients’ elementary data. For example, Temporal Association is the cue that describes the 
time duration between taking the drug and the appearance of a possible adverse event. 
What happens after the drug is stopped (Dechallenge) or re-initiated (Rechallenge) also 
provides important cues. Temporal association, rechallenge and dechallenge are all time-
related. The Abnormality in Laboratory Tests is a variable that is also extracted from 
patient’s laboratory test results. It describes the degree of the abnormality of a laboratory 
test. Other Explanations denotes alternative explanations by concurrent diseases or other 
drugs. The symptoms of an underlying disease or the one caused by another drug which is 
taken concurrently with the drug of interest cannot be differentiated from those of a 
potential ADR and thus the obtained cues (e.g., temporal association) values do not 
necessarily imply any degree of causality.  
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For Each cue input and output variables will be defined in order to be used by the 
Fuzzy Inference Engine, and each variable is fuzzified by input fuzzy sets. For a particular 
pair, the cue values are extracted from a specific patient case using fuzzy sets and rules. 
 
2.2.6.2 Fuzzy Detection Rules 
 
 
Similar Patient Finder is equipped with the detection rules that link the input 
variables to the output variables using If-Then rules with a condition and a conclusion. The 
initial detection rules and formulas are provided to the PAA by its physician based on 
his/her experience. Different experience will lead to different detection rules.  There are a 
total of 52 fuzzy detection rules. These rules will be distributed among the PAAs. This will 
be explained later in the experimental part.  The rules are distributed among the PAAs to 
imitate real life problem where each physician has his own rules based on his experience. 
As a result, each PAA will have part of the rules to emulate different levels of experiences 
of the physician users of the agents. In the real life each physician will provide his PAA 
with the preliminary detection rules based on his experience through Graphical User 
Interface. Each rule will be assigned a confidence level, a value in [0, 1]. The confidence 
level tells how much the PAAs are sure about its rules.  
  
2.2.6.3 Fuzzy Inference Engine and Defuzzifier 
 
Fuzzy Inference System follows Mamdani fuzzy model. Each detection rule will be 
evaluated and the results of the individual rules will be combined to obtain fuzzy sets of 
the cue. The evaluations of the rules and the combination of the results of the individual 
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rules are performed using Min-Max fuzzy sets operations. The cues will be extracted from 
the resulted fuzzy sets by Defuzzifier.   
 
2.2.6.4  Causality Computing Unit 
 
Causality Computing Unit contains the formulas that are used to find the causal 
relationship between a drug and a potential ADR (i.e., a signal pair). This causality 
assessment is called Degree of Causality.  When ADR Signal Pairs Detector finishes the 
identifying process, Communicator and Manager receives suspicious cases and their 
“Degree of Causality” scores in order to be sent out to the requesting agent and/or its 
physician. 
 
2.3  Rule and Confidence Level Updater 
     
Each agent in the developed system has only part of the rules representing the 
experience level of its human user. This is the case if we realistically assume that there 
does not exist a set of rules that are readily acceptable to all the users of the agents (i.e., 
physicians). The specifications of the rules vary among the agents. There are some key 
rules all the agents will have. The key rules help PAAs to make a basic signal pair decision 
(i.e., Potassium Temporal Association rules) or basic similarity finding (i.e., the rules 
involving calculating Total Laboratory Similarity and Total Similarity). Agents formulate 
their rules according to their human users’ experience. For an individual agent, these 
experience-dependent rules are incomplete, which could cause inaccurate identification of 
signal pairs. In addition, we assume realistically that we do not know which rules are right 
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or wrong. Furthermore, the numbers of patients seen by different physicians (and hence 
their agents) are different. This will affect physicians’ experience levels as well as the 
numbers of rules their agents will have. More and better rules will become available as the 
physician sees more and more patients. This fact should be reflected in the agent system 
behavior 
      The first step in allowing the agents to benefit from each other is to find a 
strategy to represent the experience of the agents for each rule. I developed a strategy 
where each rule will be assigned a confidence level, a value in [0, 1].  A rule will have a 
confidence level based on the experience of the agent having the rule. In general, to assign 
a confidence level for a given patient record set to the rule, the confidence level is defined 
as the fraction of the patient records in the set that will fire the rule.  The confidence 
level tells how much the PAAs are sure about its rules. The confidence level is calculated 
using the number of patients applicable to the rule. In other words, it represents how many 
times the PAA has used that rule. Sometimes the PAA has not used all the rules in its 
Knowledge Base. The rules that have been used should have higher confidence levels than 
those that have not been. The confidence level will be used in the process of updating and 
exchanging rules between the agents. When PAAs start collaborating with each other, each 
PAA will provide its own rules to the others.  
The agent will randomly contact one or more PAAs to be evolved in rules and 
confidence levels update. The updating occurs at programmed times. Each PAA of the 
randomly contacted agents will provide its own rules to White Board to let other PAA 
benefit from it. Rule and Confidence Level Updater uses these rules and confidence levels 
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to construct a new similarity rules and detection rules that take advantage of the experience 
of the other PAAs.  The agents will start the similarity learning process by comparing its 
own similarity factors with other agents’ similarity factors. It will add the factors that are 
not in its Similar Patient Finder. In order to do that the PAA will compare the confidence 
levels of the available rules of the missing factors and add the ones that have the highest 
confidence levels to its Similar Patient Finder. At the same time Rule and Confidence 
Level Updater updates the corresponding inputs and outputs fuzzy sets of the new rules. 
After that, Rule and Confidence Level Updater will update the other factors already exist 
in its finder. It compares the confidence level of each of its rules with the confidence level 
of the related rules in other PAAs. Then Rule and Confidence Level Updater adapts the 
rules that have the highest confidence levels. Then the corresponding inputs and outputs 
fuzzy sets are updated. The gained rules through the interaction will improve the similarity 
task performance.  
Similar procedure will be followed to update the detection rules of the ADR Signal 
Pairs Detector. Rule and Confidence Level Updater will add the cues that are not in its 
Detector from other PAAs that have the highest confidence levels. After that, the agent will 
use the same comparison methodology to update other cues that already available in its 
detector. The agent will compare the confidence level of each of its rules with the 
confidence level of the same rules in other PAAs. Then the PAA will adapt the rules with 
the highest confidence levels. Then the corresponding inputs and outputs fuzzy sets are 
updated. The gained rules through the interaction will improve the detection task 
performance. 
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Figure 4 shows an example to illustrate this methodology where PAA1 and PAA2 
are updating their rules. PAA1 has ADR detection rules involving Temporal Association 
and Dechallenge while PAA2 has ADR rules involving Laboratory Tests and Dechallenge. 
PAA1 will add PAA2’s Laboratory Tests rules to its knowledge base because it doesn’t 
have such rules. For the Dechallenge rules, PAA1 will compare its rules’ confidence levels 
with those of PAA2’s. If a PAA2’s rule’s confidence level is higher, PAA1 will adopt 
PAA2’s Dechallenge rule by overriding its own Dechallenge rules. At the same time, 
PAA2 follows the same procedure in updating its rules involving Laboratory Test and 
Dechallenge rules. 
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Figure 4.  Updating ADR signal pair detection rules in two PAAs. 
 
The confidence level of a rule will be updated each time a rule has been used either 
for evaluating a new or old case. The physician can input new rules to the system at any 
time through sending a request to Communicator and Manager which then forward the 
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request to Rule and Confidence Level Updater. Rules and Confidence Level Updater add 
the new input rules from the agent’s physician to the agent similarity or detection rules.   
The confidence level will affect the contribution of the rule. For instance, if the 
system assigns a confidence level of 0.4 for a rule “If Potassium Laboratory Test Value is 
Low, then Abnormality in Potassium Laboratory Test is Low” it means there is a 40% 
confidence on that rule. This will affect the output of that rule which consequently affect 
the calculation of the Total Potassium Temporal Association.  
For example if there a scene that contains PAA1 and PAA2. For the meantime let’s 
assume that the only factor used by PAAs in the scene is the age factor and it is just 
contains one Age rule in its decision. Let’s say that the total number of cases used Age 
rules before for PAA1 =22 and the total number of patients in the PAA1 Database is 30 
patients. Suppose that PAA1 is evaluating a new case. Then PAA1 will do the following: 
 
Step 1: PAA Confidence Level Update  
In this step the PAA will update its rules based on the new patient case.  Let’s 
assume that PAA1 used in that evaluating his Age rule. This will increase the total number 
of cases used age rule by one. Besides, the total number of patients will be increased also 
to 31. The confidence level will be updated using the following rule: 
 
Confidence Levels of Age rules = Total number of cases used Age rules / Total 
number of patients in the PAA1 Database. 
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So the confidence level will be updated from 22/30= 0.73 to 23/31= 0.74. In case 
the new Confidence level is lower than the new confidence level, the new confidence will 
stay the same as the old one. 
 
Step 2: Confidence Level Update using Other Agents’ Rules 
 In this step, the PAA will communicate with other agents in the scene. PAA1 will 
look at other agents’ confidence level for the age rule. If the agent finds another agent with 
higher confidence level, not necessarily the highest, PAA1 will update its age rule and 
adapt the other agent rule with the new confidence level. PAA1 confidence level is 0.74 for 
the Age rule as described in step 1. Let’s assume PAA2 confidence level is 0.85. Then 
PAA1 will adopt PAA2 Age rule and will use PAA2 confidence level’s value in future 
evaluation because by adapting these rules  PAA1 will benefit from the experience of the 
PAA2 which is shown here as a rule. The new confidence level for PAA1 will be 0.85. This 
step is summarized in Table 2 for this sense.  
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Table 2. Steps to update confidence levels for the example PAA1 and PAA2. 
 
 
                       Agent    
Step      
 
PAA1 PAA2 
 
 
 
 
 
 
 
1 
 
 
Number of times the age 
rule has been used is 22. 
 
Number of times the 
age rules has been used 
is 79. 
Total Number of Patients 
used in updating the 
confidence Level is 30. 
Total Number of 
Patients used in 
updating the 
confidence Level is 88. 
Calculate the confidence 
level for the age rules using 
the following formula 
Age_CL PAA1= 22/ 
30=0.733. 
Calculate the 
confidence level for the 
age rules using the 
following formula 
Age_CL A2= 79/ 
88=0.897 
2 New patient needs to be 
evaluated. 
N/A 
3 
 
The new confidence level 
will be 0.74. 
No change to the 
confidence level. 
4  
 
PAA1 asks PAA2 for help. PAA2 received the 
request and accept 
providing the help. 
5 Communication is provided between the two PAA to 
talk with each other and help each other. 
6 Comparing the confidence level for the age rule to see 
which agent has more experience in Age than the 
other. 
Here let’s assume that PAA1 Confidence level is 
lower that PAA2 Confidence level. 
7 Agent 1 Adopt Agent 2 age rules. 
 
8 If another new case needs to 
be evaluated by PAA1 
The new confidence level 
will be equal to 
0.897. 
If another new case 
needs to be evaluated 
by PAA2 
The confidence level 
will be equal to 
0.897. 
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2.4 Agent Communication Behaviors and Agnet Team Construction 
 
 
Agents can have different roles and abilities with different (for instance, hospital, 
physician). Agents are communicating between each other using certain communication 
protocols. The main components of any multi-agent system implementation are: the agents 
and their roles, the dialogic framework, the scenes, the performative structure, and the 
normative rules [40, 41]. In a health organization system, agents play the roles of 
physicians, pharmacists, epidemiologists, and so on [72, 73]. The agent playing a given 
role must follows the pattern of behaviors and scenarios initially provided by system 
designer and later by his human user.  
The communication protocols used between agents have to be fixed. Agents 
interact through speech acts language.  For example  query, inform, request, offer, accept, 
withdraw, and reject speech acts has been used in the developed system .Interaction 
between agents occurs within a scene. The developed system composed several scenes 
which are basically group meeting composed of a set of agents playing different roles and 
communicating with a well-defined communication protocol. To specify a scene, the first 
step is to identify which are the agents that will participate in the scene. Agents with 
different roles can enter and exit a scene to go to another one. The second step is to define 
the communication protocol [72, 73].  
A scene can be described as a graph, which can be regarded as a state diagram. The 
nodes represent different states of a conversation and the arcs are labeled with expressions 
of the communication language making the conversation passes from one state to another. 
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The graph has a single initial state and a set of final states representing different endings of 
the conversation.  
Figure 5 shows the state diagram of a scene how three agents, PAA1, PAA2 and 
PAA3, have a conversation. A communication protocol will be used in the communication 
request of PAA1 to PAA2 and PAA3 in order talk about an ADR signal pair. Initially, the 
conversation is in state S0. Then PAA1 initiates the conversation and the system enters the 
next state S1. Several possibilities then open up. PAA2 and PAA3 may accept or reject the 
request. Depending on their answers, the next state will be S2 if both agents accept, S3 if 
only PAA2 accepts, S4 if only PAA3 accepts or S5 if both reject. If the task has been 
successfully completed, state S6 will be reached. Otherwise state S7 will be reached. 
 
Figure 5.  The state diagram of a scene involving three PAAs. 
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To describe what is happening during a conversation between two PAA agents, 
Petri nets can be used (Figure 6 shows an example). Petri nets have a number of 
advantages when used to analyze conversations in multi-agent systems [40]. A Petri net is 
defined as an oriented graph comprising two sorts of nodes: places and transitions [40]. 
This graph is constituted in such a way that the arcs can only link places to transitions or 
transitions to places. Places are graphically represented by circles and transitions by bars. 
The places correspond to the state of the agent during a conversation stage. The transitions 
correspond either to synchronization due to the receipt of messages or to conditions of 
actions. Places IA and IB describe the initial states where the PAAs find themselves before 
the beginning of the conversation. Places FA1, FA2, FB1 and FB2 represent the end of 
conversation states. Starting from state IA, PAA1 sends a request “to do (T)” to PAA2 and 
moves in to state WA1, which represents waiting for a response. If PAA2 can’t do the task, 
it sends a refusal to PAA1, which then goes into state FA1, which indicates that PAA1 
must look elsewhere to have its task carried out. If PAA2 can do the task, it sends an 
acceptance message to PAA1, which places PAA1 into wait for a response state WA2. 
During this time, PAA2 is in state WB, while trying to carry out the task. Once finishing 
the task, it sends a notification of end of accomplishment to PAA1, which places PAA1 in 
state FA2 and places PAA2 in state FB2. If not, PAA2 indicates that it cannot do the task, 
which places PAA1 in state FA1 and places PAA2 in state FB1. 
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Figure 6.  Conversational model of an ADR task between two PAAs using the Petri nets 
approach. 
 
In real life problem we have a lot of physicians in the same or different health 
organization. It’s reasonable to find a way to divide the PAAs into different teams and each 
team can focus on a certain ADR. This will faster the process of signal pair identification 
and reduces communication overhead. Also I need to take in my account that a new PAA 
can join a team at any time and it need to join the correct team.  
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The agent in the developed system can be added to a team according to the name of 
medication (and its class) and the potential adverse event. To do that, a strategy of 
classifying medications is needed and required to be included the identification system. 
The National Drug Code System [74] was chosen as a therapeutic or pharmacological 
classification technique . The National Drug Code provides each medication by a unique 
10-digit number which is composed of 3-segment. Each segment provides certain 
information. The first segment provides 4 or 5 digits to describe the medication labeler. A 
labeler is any firm that manufactures, repacks or distributes a medication.  The second 
segment provides 3 or 4 digits to the actual contents of a medication product including 
doses and formulation. The third segment provides 1 or 2 digits that description of the 
trade package such as forms of the medication (for example tablets or liquid) and sizes (or 
number of tablets).  
Table 3 shows example for those codes for drug LISNOPRIL. In some exceptional 
cases, the second and third segments may contain characters besides digits.  
  
Table 3. Examples of National Drug Codes for Drug Lisinopril. 
 
 
 
The drug name will be extracted from the query sent by the agent. Then the drug 
name will be converted using National Drug Code Directory to 10 digits. For example if 
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the agent are interested in Lisinopril drug regardless the dose then the first segment, i.e. 
0143, will be used. After that, the white board agent checks whether a team for this drug 
class already existed. If not, a new team would be created and registered to the main 
container based on the NDC number. 
 
  2.5 System Implementation 
 
For system construction and execution, JADE 3.7 agent platform (Java Agent 
DEvelopment Framework) is adopted [60].  JADE is an open-source software framework. 
JADE is a widely used package in multi agent system implantation [75]. JADE is 
following the specifications laid by The Foundation for Intelligent Physical Agents (FIPA) 
for multi agent system implementations [42]. It provides a set of Java classes that makes it 
easy to implement the systems. JADE can run on a variety of operating systems including 
Windows and Linux.  
 
 
2.5.1 JAVA Agent Development Framework  
 
The JADE platform includes most of agent’s specifications. Each agent is 
implemented in JADE as a single thread. JADE provide a multi thread environment that 
allows the agents to execute parallel tasks. Different cooperative behaviors can effectively 
schedules in JADE. JADE incorporates some ready to use behaviors that commonly used 
by agents during performing certain task. Among the others, JADE offers a behavior that 
allows full integration with JESS which is a rule based engine that performs all the 
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necessary reasoning.  JADE provides follows FIPA standers. JADE consists of the 
following three parts 
1. A runtime environment where agents can perform the requires task, 
2. A library of classes which are used in the design of multi-agent system, 
3. Graphical User Interfaces that can be used for debugging the designed system and 
monitor the actions of certain agents. 
 
In brief, JADE runtime environment consists of two essential built-in agents 
namely Agent Management Service (AMS) and Directory Facilitator (DF).The multi agent 
system cannot operate without the Agent management service agent while it can without 
the directory facilitator (DF) agent. The AMS is responsible for managing the interactions 
of the agents in the system. To that AMS agent is responsible for registering and naming 
any agent join the system or being created. It keeps all the agent names beside some 
description about the location of agents. The Directory Facilitator agent maintains a 
description of the services that the agents are ready to provide to the others. Any registered 
agent can use the DF agent to search for specific services or help that can be handled by 
other agents. At the same time any agent can use the DF agent to announce for its own 
services that are available to other. Since agent are normally distributed at different 
location. Each location will have a runtime environment that hosts the agents, which is 
called a “Container”. Each container has AMS and DF agents. The containers will 
communicate with each other using a pre defined protocols. Agents live in the containers. 
All the dissections  and interactions between agents take place in JADE containers[75]. 
68 
 
 
One container needs to be assign as main container which represents the bootstrap point of 
a platform. It is the first container to be launched and all the other containers must join it 
by registering with it. For my system, the main container hosts four PAAs (I choose four 
because it is representative enough while computing time is still reasonable). 
Agents will be assigned a unique identifier and an address that will be used to 
register the agent in its container. This agent life-cycle management allows effective 
communication between agents. JADE also provides tools that manage both locally and 
remotely agent life cycles including create, suspend, resume, freeze, thaw, migrate, clone 
and kill. 
JADE provides flexible communication architecture to be used by the agents. 
JADE provides messaging system that follows FIPA_ACL standers. The messaging 
system manages message traffics and monitors the resulted queues provided to agents. 
JADE provides the agents with different modes to access their. The full FIPA 
communication model has been implemented in JADE and all its components have been 
integrated including the interaction protocols.  Agent ontology management has been also 
implemented besides allowing the user to implement user-defined ontologies that allow 
agents to communicate easily and effectively. JADE allows the use of Web which will 
provide the multi-agents system with several services that can enhance the job of the 
agents. 
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2.5.2 Java Classes 
 
During the development of the system with JADE, the following types of Java code 
classes are created and implemented: 
Agent classes, which is used for describing the agent types. In this category I have 
utilized (1) class HOAs that implements Health Organization Agents, (1) class PAA that 
implements PAAs, and (2) class DBWA that implements Database Wrapper Agents. An 
agent is implemented in JADE by extending the provided Agent class and overriding the 
default implementation of the methods that are automatically invoked by the platform 
during the agent lifecycle, including setup() and takedown(). In the implementation stage 
all agent classes extend the Agent base class. The Agent Activity classes will be called in 
Agent classes. 
Agent Activity classes, also called behaviors, which are used for describing the 
activities performed by the agents in the system. Agent actions are normally specified 
through behavior classes. It describes and gives specifications of possible dialogues and 
scenarios the participating agents could face. A behavior is implemented in JADE by 
extending the provided Behavior Base class. In the implementation I have used Java 
classes for defining behaviors that describe the agent’s responses to FIPA messages, like 
INFORM and SUBSCRIBE. The agents communicate only using FIPA defined language. 
A behavior is implemented in JADE by extending the provided Behavior abstract base 
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class. The class Behavior is the root of a class hierarchy abstracting various agent behavior 
types. 
Reasoning classes, which are used for the implementation of the various reasoning 
models and Fuzzy Inference Engine employed by PAAs, for example, the Fuzzy Similar 
Patients Finder employed by PAAs. Here I use FuzzyJess Toolkit from the National 
Research Council of Canada's Institute for Information Technology. It is a set of Java 
classes that provide the capability for handling fuzzy concepts and reasoning [7]. It is 
compatible with JADE. It allows the user to use Java language to define membership 
functions, set antecedent and consequent of a fuzzy rule, and makes a fuzzy inference. 
FuzzyJess uses Jess (Java Expert System Shell). Jess provides the basic elements of an 
expert system, including fact-list, knowledge base that contains all the rules, and an 
inference engine which controls overall execution of the rules. Jess includes a special class 
called Rete, which is used to embed Jess in JADE.  
Ontology classes, which are necessary for implementing the agent communication 
semantics using concepts and relations. Ontology classes are implemented using a set of 
Java classes. An Ontology class is implemented by extending the provided Ontology 
Abstract Base class. 
Graphical User Interface (GUI) classes, which provide the user with a graphical 
interface to the multi-agent system, initiate a search, and show the results of a query to the 
user. Figure 7 shows the GUI of the developed system. 
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Figure 7.  The GUI of the developed system. 
 
White Board classes, JADE provides the classes used to help an agent publish and 
search for services through method calls. These classes help agents use the White Board.  
Inter-agent Protocols implantation classes, protocols are implemented in JADE 
using special kind of behaviors which are responsible for proper ordering of the message 
sequences for protocol they implement.  
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CHAPTER 3  
FINDING SIMILAR PATIENTS IN THE MULTI AGENT 
ENVIRONMENT 
 
Early detection of unknown ADRs could save patient lives and prevent unnecessary 
hospitalizations. In this dissertation, I developed a multi-agent system for ADR detection. 
In the developed system, an agent is assigned to a physician to play an assist role. Through 
the study, I encounter the interesting problem of how the agents should collaborate to find 
patients in their patient databases that are similar to any given patient provided by one of 
the agents as a prototype. Actually, finding similar patients is one of the important steps 
toward ADR detection in a multi-agent setting. This would also be a necessary step in 
many other medical applications of multi-agent systems. 
At the same time it is complicated to find similar patients in a multi-agent 
environment especially if I realistically assume that there does not exist a set of similarity-
finding rules that are readily acceptable to all the users of the agents (i.e., physicians). This 
is because no two patients are identical and “similar” is really a vague, subjective measure 
rather than an objective measure. Furthermore, physicians often disagree one another 
owing to their knowledge and experiences. The specifications of the similarity-finding 
rules vary among the agents. Agents formulate their similarity rules according to their 
human users’ experience. For an individual agent, if these experience-dependent rules are 
incomplete, it could cause inaccurate determination of similar patients. In addition, we 
assume realistically that we do not know which rules are right or wrong. Furthermore, the 
numbers of patients seen by different physicians (and hence their agents) are different. This 
will affect physicians’ experience levels as well as the numbers of rules their agents should 
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have. More and better rules should be used as the physician sees more and more patients. 
This fact should be reflected in the agent system behavior. It should be obvious that these 
dynamic issues will pose challenges when the agents work collectively to help one another 
to reach a common goal (e.g., ADR detection).  
In this dissertation, I developed a new methodology for finding similar patient in 
the multi agent system[69]. In that system, a similar patient search starts when an agent 
sends a request along with the patient of interest to the rest of the agents in the system to 
help in finding similar patients. The agents will start collaboratively one another in a way 
that the more experienced agents will help the less experienced agents in updating the 
similarity rules. Each agent will provide its similarity rules to the other agents. Then, the 
agents will retrieve patient cases one by one from their databases in order to evaluate their 
own cases using the new, updated similarity rules. The other agents will forward the 
similar cases along with their similarity scores to the requesting agent who may present the 
result to its user - physician.   Having similar cases will provide the requesting agent with 
more evidence about the interested case and thus helps in decision making by the agent or 
by its physician.  
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3.1 Design of the Similar Patient Finder 
 
Patient similarity is characterized by a number of factors related to physician's 
experience. In this dissertation finding the similarity between a reference patient and 
compared patients in the local databases is based on temporal association of a medication 
of interest, abnormality of a laboratory test, Symptoms and morbidities(chronic and acute), 
age, and medications.  
 The similarity rules used in the experimental part were acquired from the 
physicians on the team through the joint efforts of the engineering and medical team 
members after a careful analysis of the relevant literature. There are a total of 38 fuzzy 
rules.  
     
3.1.1 Temporal Association of Medication Similarity 
 
 
Temporal association gives the relationship between the time of taking a drug and 
the time of symptom occurrence. This time duration is called Symptom Appearance 
Duration. It should be noted that in the case of a potential ADR, exposure to a drug should 
always precede the effect (symptom). This distinction is important because the effect might 
result from entirely different causes (e.g., underlying diseases or reception of another 
medication). 
For example if we assume Enalapril is the interested drug and we have the situation 
which is shown in Figure 8. In this case, since the ICD-9 code 729.1 (myalgia) occurs 
before all the start dates of Enalapril, it cannot be considered as an adverse event caused by 
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that drug. The ICD-9 code 786.2 (cough) occurs after the first start date of Enalapril in 24 
days. Thus it can be caused by the drug.  
 
 
Figure 8. Example of possible ADR event. 
 
Based on the experience of the physicians on the team, we define the following 
fuzzy rules to link cause (drug) to effect (ADR): 
 If Symptom Appearance Duration is Short Then Temporal Association is Likely. 
 If Symptom Appearance Duration is Medium Then Temporal Association is Possible. 
 If Symptom Appearance Duration is Long Then Temporal Association is Unlikely. 
Both Symptom Appearance Duration and Temporal Association are variables 
characterized by triangular fuzzy sets. Figure 9 and Figure 10 show the fuzzy sets for 
Symptom Appearance Duration and Temporal Association, respectively. 
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Figure 9. Fuzzy sets for Symptom Appearance Duration. 
 
 
Figure 10. Fuzzy sets for Temporal Association. 
      
       Temporal Association Distance is the distance between the Temporal Association of 
the reference patient and a patient being compared with. It is defined as follows: 
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Temporal Distance = | Temporal Association of reference patient - Temporal Association 
of a patient being compared | 
      
     The similarity between a reference patient and a compared patient of a factor resulted 
from Fuzzy Inference Engine is given by: 
||1),( yxyxSimilarity   
Since x and y are values between 0 and one then Similarity will be the same.  Roughly 
speaking, the distance which is given by | x - y| is comparing “how far the similarity 
factors are,” so its negation will point out “how similar they are.”    This equation is called 
local similarity measure.  
Based on that, the Temporal Similarity between the reference patient and the 
compared patient is calculated using: 
Temporal Similarity = 1- Temporal Distance 
 
The resulted similarity value will be between 0 and 1.   
   
3.1.2 Laboratory Test Similarity 
 
This section discusses the rules used to determine similarity based on Laboratory 
Tests, which include Creatine phosphokinase (CPK) Laboratory Test (also known as 
Creatine Kinase (CK)), Transaminases Laboratory Test (either ALT or AST), Creatinine 
Laboratory Test and Potassium Laboratory Test. These laboratory tests are mainly used in 
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ADRs detection study. Most people with adverse event in the early stages feel well and 
have no clear symptoms that would lead a health care provider. This place a large emphasis 
on laboratory tests to diagnose, predict or evaluate a medical problem since they are 
indicative of extensive problems in the patient. The liver for example is one of the organs 
that can be affected from medications. The liver has several functions and it is usually 
called the body’s manufacturing and filtering unit. The Alanine Aminotransferase (ALT) 
and Aspartate Aminotransferase (AST) laboratory test are typically used to evaluate liver 
functions or liver injury. Elevation of these tests is reflects a damage to the liver cell. 
Another example is the CK test. The elevation of CK laboratory result rise when muscle or 
heart cells are injured. Abnormality of a laboratory test shows the degree of elevation of a 
laboratory test result. 
For each laboratory test, the laboratory result will be converted to its abnormality 
value. The interpretation of abnormality value of laboratory test results is very important to 
understand the situation of the patients. The abnormality value will be zero for the 
laboratory results in normal ranges. For other ranges, The Abnormality value will be 
calculated using fuzzy Inference system. The laboratory results will be the input to the 
system and the Abnormality value will be the output.  Both the input and the output are 
fuzzy variables. 
First, the Abnormalities of laboratory tests will be calculated for both the reference 
patient and the compared patient. Then the distance measure between these two values will 
be founded. Finally the similarity value between the reference patient and the compared 
patient is calculated. The resulted similarity value will be in the range of 0 and 1. The 
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similarity between two exact patients the similarity is one. If two patients are totally 
different the similarity is one. The abnormalities ranges used in defining the fuzzy rules 
and the membership functions of the fuzzy variables differ according to the characteristics 
of the laboratory test.  
For example for the laboratory test AST, there are five fuzzy sets for the variable 
Laboratory Test Value as input- Very Low, Low, Medium, High and Very High (Figure 11), 
and five fuzzy sets as output to define the variable Abnormality in Laboratory Test:  Very 
Low, Low, Medium, High and Very High (Figure 12).  
        
The rules used to determine Abnormality in AST Laboratory Test are as follows, 
 If AST Laboratory Test Value is Very Low, then Abnormality in AST Laboratory 
Test is Very Low. 
 If AST Laboratory Test Value is Low, then Abnormality in AST Laboratory Test is 
Low. 
 If AST Laboratory Test Value is Medium, then Abnormality in AST Laboratory Test 
is Medium. 
 If AST Laboratory Test Value is High, then Abnormality in AST Laboratory Test is 
High. 
 If AST Laboratory Test Value is Very High, then Abnormality in AST Laboratory 
Test is Very High. 
    These fuzzy rules are extracted from the knowledge provided by the physicians in our 
team. 
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Figure 11. Fuzzy sets for AST Laboratory Test Value. 
 
 
Figure 12. Fuzzy sets for Abnormality in AST Laboratory Test. 
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Then AST Laboratory Abnormality Distance, which is the distance between the 
Abnormality in AST Laboratory Test of the reference patient and that of a patient being 
compared with, is calculated using the following definition: 
 
AST Laboratory Abnormality Distance = | Abnormality in AST Laboratory Test of 
reference patient – Abnormality in AST Laboratory Test of patient being compared | 
       
AST Laboratory Similarity will be found based on the Laboratory Abnormality using the 
following rules, 
AST Abnormality Similarity = 1- AST Laboratory Abnormality Distance 
 
The same procedure will be followed for other laboratory tests. Here are the rules and the 
fuzzy sets for ALT, CK, Potassium and Creatinine laboratory tests. 
 
    The rules used to determine Abnormality in ALT Laboratory Test are as follows, 
 If ALT Laboratory Test Value is Very Low, then Abnormality in ALT Laboratory 
Test is Very Low. 
 If ALT Laboratory Test Value is Low, then Abnormality in ALT Laboratory Test is 
Low. 
 If ALT Laboratory Test Value is Medium, then Abnormality in ALT Laboratory Test 
is Medium. 
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 If ALT Laboratory Test Value is High, then Abnormality in ALT Laboratory Test is 
High. 
 If ALT Laboratory Test Value is Very High, then Abnormality in ALT Laboratory 
Test is Very High. 
       The fuzzy sets used to determine ALT Laboratory Test Value are shown in Figure 13. 
The Abnormality in ALT Laboratory is a fuzzy variable whose fuzzy sets are shown in 
Figure 14. 
 
 
Figure 13. Fuzzy sets for ALT Laboratory Test Value. 
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Figure 14. Fuzzy sets for Abnormality in ALT Laboratory Test. 
 
Then ALT Laboratory Abnormality Distance, which is the distance between the 
Abnormality in ALT Laboratory Test of the reference patient and that of a patient being 
compared with, is calculated using the following definition: 
 
ALT Laboratory Abnormality Distance = | Abnormality in ALT Laboratory Test of 
reference patient – Abnormality in ALT Laboratory Test of patient being compared | 
 
ALT Laboratory Similarity will be found based on the Laboratory Abnormality using the 
following rules, 
ALT Abnormality Similarity = 1- ALT Laboratory Abnormality Distance 
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    The rules used to determine Abnormality in CK Laboratory Test are as follows, 
 If CK Laboratory Test Value is Very Low, then Abnormality in CK Laboratory Test 
is Very Low. 
 If CK Laboratory Test Value is Low, then Abnormality in CK Laboratory Test is 
Low. 
 If CK Laboratory Test Value is High, then Abnormality in CK Laboratory Test is 
High. 
 If CK Laboratory Test Value is Very High, then Abnormality in CK Laboratory Test 
is Very High. 
 
Both CK Laboratory Test and Abnormality in Ck Laboratory are fuzzy variables 
and their fuzzy values are represented by bell shaped membership functions. Figure 15 
shows the CK Laboratory Test. The Abnormality in Ck Laboratory is shown in Figure 16). 
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Figure 15. Fuzzy sets for CK Laboratory Test Value. 
 
 
Figure 16. Fuzzy sets for Abnormality in CK Laboratory Test. 
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Then CK Laboratory Abnormality Distance, which is the distance between the 
Abnormality in CK Laboratory Test of the reference patient and that of a patient being 
compared with, is calculated using the following definition: 
 
CK Laboratory Abnormality Distance = | Abnormality in CK Laboratory Test of reference 
patient – Abnormality in CK Laboratory Test of patient being compared | 
     CK Laboratory Similarity will be found based on the Laboratory Abnormality using the 
following rules, 
CK Abnormality Similarity = 1- CK Laboratory Abnormality Distance 
 
    The rules used to determine Abnormality in Potassium Laboratory Test are as follows, 
 If Potassium Laboratory Test Value is Low, then Abnormality in Potassium 
Laboratory Test is Low. 
 If Potassium Laboratory Test Value is Medium, then Abnormality in Potassium 
Laboratory Test is Medium. 
 If Potassium Laboratory Test Value is High, then Abnormality in Potassium 
Laboratory Test is High. 
Potassium Laboratory Test Value is a fuzzy variable and its fuzzy values are shown 
in Figure 17. The fuzzy sets used to determine Abnormality in Potassium Laboratory Test 
is shown in Figure 18. 
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Figure 17. Fuzzy sets for Potassium Laboratory Test Value. 
 
 
Figure 18. Fuzzy sets for Abnormality in Potassium Laboratory Test. 
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Then Potassium Laboratory Abnormality Distance, which is the distance between 
the Abnormality in Potassium Laboratory Test of the reference patient and that of a patient 
being compared with, is calculated using the following definition: 
 
Potassium Laboratory Abnormality Distance = | Abnormality in Potassium Laboratory Test 
of reference patient – Abnormality in Potassium Laboratory Test of patient being 
compared | 
AST Laboratory Similarity will be found based on the Laboratory Abnormality using the 
following rules, 
Potassium Abnormality Similarity = 1- Potassium Laboratory Abnormality Distance 
 
The rules used to determine Abnormality in Creatinine Laboratory Test are as follows, 
 If Creatinine Laboratory Test Value is Low, then Abnormality in Creatinine 
Laboratory Test is Low. 
 If Creatinine Laboratory Test Value is High, then Abnormality in Creatinine 
Laboratory Test is High. 
 
The Creatinine Laboratory Test Value that is used to determine Abnormality in 
Creatinine Laboratory Test. Both variables are characterized by bell fuzzy sets (Figure 19 
and Figure 20) 
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Figure 19. Fuzzy sets for Creatinine Laboratory Test Value. 
 
 
Figure 20. Fuzzy sets for Abnormality in Creatinine Laboratory Test. 
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Then Creatinine Laboratory Abnormality Distance, which is the distance between 
the Abnormality in Creatinine Laboratory Test of the reference patient and that of a patient 
being compared with, is calculated using the following definition: 
 
Creatinine Laboratory Abnormality Distance = | Abnormality in Creatinine Laboratory 
Test of reference patient – Abnormality in Creatinine Laboratory Test of patient being 
compared |. 
      
Creatinine Laboratory Similarity will be found based on the Laboratory Abnormality using 
the following rules, 
 
Creatinine Abnormality Similarity = 1- Creatinine Laboratory Abnormality Distance. 
 
   The aggregated laboratory abnormality similarity between the referenced patient and the 
compared patient is calculated as a linear combination of the corresponding sub 
abnormality similarities. The aggregated Laboratory Abnormality Similarity is computed 
as the following: 
 
Laboratory Abnormality Similarity = w1 x AST Abnormality Similarity + w2 x ALT 
Abnormality Similarity + w3 x CK Abnormality Similarity + w4 x Potassium Abnormality 
Similarity + w5 x Creatinine Abnormality Similarity. 
         where   w1 + w2 + w3 + w4 + w5 =1 
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The weights control the importance of the sub similarities. In ADR problem some 
laboratory abnormalities are more important that the other based on the studied medication. 
This makes some weights greater than the others. For example in case of Statin drugs, the 
importance of laboratory tests AST, ALT, and CK is higher than the importance of 
Potassium and Creatinine laboratory tests. The opposite is valid in the case of Inhibitor 
Drugs. In this study I deal with these sub similarities in equal amount of importance. In 
case of equally importance  
 
3.1.3 Symptom and Morbidity Similarities 
 
To find the similarity based on morbidities the International Classification of 
Diseases, 9th Revision, and Clinical Modification (ICD-9-CM) code will be used. The 
ICD-9 code provides codes to classify diseases and a wide variety of signs, symptoms, 
abnormal findings, complaints, social circumstances, and external causes of injury or 
disease. Every health condition is assigned a unique category and given a unique code.  For 
example, if a patient is diagnosed with Hepatitis C, he/she will be given the ICD-9 code 
“070.51“. If the diagnosis is for something acute, something that goes away with treatment 
like a rash or the flu, then the ICD-9 code will be less important because the illness or 
condition will go away. However, if the patient is diagnosed with a chronic or lifelong 
problem, like heart disease or diabetes, the ICD-9 code will be more important and will 
affect his future medical care.  
Since different ICD-9 codes may represent the same (or similar) diagnoses, I 
clustered the ICD-9 codes into a manageable number of categories based on the clinical 
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classifications system (CCS) for the ICD-9-CM fact sheet Developed at the Agency for 
Healthcare Research and Quality [76], the CCS groups over 13,600 ICD-9 codes into 285 
mutually exclusive and clinically meaningful categories. The clinical classifications system 
makes it easy for physicians and hence their agents to understand patient cases and analyze 
them for similarity task.  
 
In order to find the similarity based on ICD-9s, the ICD-9 codes of the reference 
patient and the compared patients will be converted to the corresponding CCS categories.  
Some of the CCS categories are of importance that will be used in finding similar patients 
while the other will be discarded. 
To find ICD-9 similarity between the reference patient and the compared patients, 
the ICD-9 of the reference patient and the compared patient is converted to their 
corresponding CCS Categories. Then the duplicated CCS categories resulted from 
converting different ICD-9 codes that belong to the same CCS category will be removed. 
Finally, the similarity between the two resulted CCS Categories is calculated using Jacard 
Coefficients as shown in the following steps 
 
Step 1: 
Convert the ICD-9 of the reference patient to their CCS Categories. 
Step 2: 
Convert the ICD-9 of the compared patients to their CCS Categories. 
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Step 3: 
Remove the duplicated categories resulted from the conversion of different ICD-9 
codes belonging to the same CCS category. 
Step 4: 
The two new CCS vectors will be compared to find how many categories are in 
common.  
 
where Jacard coefficients are defined as follows, 
MS01 is the number of CCS categories where reference patient has them and 
compared patient doesn’t. 
MS10 is the number of CCS categories where reference patient doesn’t have them 
and compared patient has them. 
MS11 is the number of CCS categories where both reference patient and compared 
patient have them. 
 
Example: 
Reference patient has 5 CCS categories= {93,105,125,200,242} and the compared 
patient has 6 CCS categories = { 93,106,107,126,200,242}.  
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The CCS Categories set is the union of both CCS categories sets founded in the 
reference patient and the compared patient. In this example the CCS Categories set is { 
93,105,106,107,125,126,200,242} 
 
CCS 
Categories 
 
93 105 106 107 125 126 200 242 
Reference 
patient 
Yes Yes No No Yes No Yes Yes 
Compared 
patient 
Yes No Yes Yes No Yes Yes Yes 
 
Then the Jacards coefficients are calculated as shown: 
MS01 =2 
MS10 = 3 
MS11=3 
Then the Symptoms and Morbidities Similarities = (3)/ (2+3+3) =3/8. 
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3.3.4 Age Similarity  
  
Age is an important factor in determining the similarity between the patients 
because some symptoms are potentially will be considered more serious according to age. 
For example, acute diarrhea in an adult is not that danger as in an elderly patient which 
could produce dehydration more quickly;  
Based on the literature and the physicians on our team, the age of a patient will be 
classified to one out of four groups. These groups are: 
  Group 1: Age is below 35 years. 
  Group 2: Age is between 35 and 69 years. 
  Group 3: Age is Between 70 and 90 years. 
  Group 4: Age is greater than 90 years.  
 
The Age similarity between the age of reference patient and the age of compared 
patient will be calculated as follows: 
 
Rule 1: 
    If the two ages belongs to the same Age Group, then the Similarity will be equal to 1.00. 
 
Rule 2:  
    If Rule 1 not satisfied and the two ages belong to different groups, the similarity will be 
calculated as follows: 
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      Step 2-1: The difference between the age of the reference patient and the age of the 
compared patient is calculated using this equation: 
 
Age Distance = | Age of reference patient - Age of compared patient|. 
       
     Step 2-2: Use the Age Distance to fire the Age Similarity fuzzy rules which are 
deduced as shown below: 
 If Age Distance is Very Short, then Age Similarity is Very High. 
 If Age Distance is Short, then Age Similarity is High.           
 If Age Distance is Large, then Age Similarity is Low.        
 If Age Distance is Very Large, then Age Similarity is Very Low. 
 
The input Age Distance is defined by the following membership functions: Very 
Short, Short, Large, and Very large. The output of the fuzzy logic, the Age similarity, is 
defined by four membership functions very low (V L), low (L), High (H), and Very High 
(VH). The centroid method is used for defuzzification. Both Age Distance and Age 
Similarity are represented by triangular membership functions (Figure 21 and Figure 22).  
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Figure 21. Fuzzy sets for Age Distance. 
 
 
Figure 22. Fuzzy sets for Age Similarity. 
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3.3.5 Medication Similarity 
 
The Medication Similarity plays a key role in identifying ADR since an adverse 
event can change by changing the medication. Sometimes the resulted adverse events are 
pleasant as in the case of some out of counter medications that are used to treat various 
mild conditions and diseases such as pain relievers and fever reducers. However, 
sometimes, the resulted adverse events are dangerous and can cause a great harm to human 
body.  
Finding medication similarity is based on three factors which are Medication Name 
Medication Class and Medication Quantity.     
The procedure for finding similarity based on medication is shown in steps A to D: 
 
Step A: Medication Name Similarity 
 
 To find similarity based on medication name, all Drugs the reference patient and 
the compared patient took will be retrieved. Then the duplicated drug names in each of the 
retrieved lists will be removed. After that the drug doses attached to the drug name will be 
removed. The two drug lists will be compared to find the similarity using Jacard 
coefficients as shown below: 
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Step A.1: 
Remove the duplicated drug names from the retrieved list of the reference patient. 
Step A.2: 
Remove the duplicated drug names from the retrieved list of the compared patient. 
Step A.3: 
The two new Drug lists will be compared. The Drug Name similarity is calculated 
using the Jacard Coefficients:  
 
where, 
MD01 is the number of Drug Agents that the reference patient has them and compared 
patient doesn’t. 
MD10 is the number of Drug Agents that the reference patient doesn’t have them and 
compared patient has them. 
MD11 is the number of Drug Agents where both the reference patient and the compared 
patient have them. 
The resulted Drug Similarity will be between 0 and 1 
 
Example: 
Reference patient has 3 Drug Agents={ Rosuvastatin, Simvastatin, Captopril}  and the 
compared patient has 4 Drug Agents ={ Simvastatin, Captopril, Enalapril, Benazepril}.  
The Drug Agents set is the union of both Drug Agents founded in Reference patient 
and compared patient.  
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In this example the Drug Agents set is {Rosuvastatin, Simvastatin, Captopril, 
Enalapril, Benazepril}.  
 
Drug Name 
 
Rosuvastatin Simvastatin Captopril Benazepril Enalapril 
Reference 
patient 
Yes Yes Yes No NO 
Compared 
patient 
NO Yes Yes Yes Yes 
 
Then the Jacards coefficients are calculated as shown: 
MD01 =1 
MD10 =2 
MD11=2 
Then Medication Name Similarity = (2)/ (1+2+2) =2/5. 
 
 
 
Step B: Medication Classes Similarity 
A drug may be classified by the chemical type of the active ingredient or by the 
way it is used to treat a particular condition. To achieve this, we need to find a strategy of 
classifying drugs available in the market and then use it in the developed framework. The 
medications were catalogued according to the Anatomical Therapeutic Chemical 
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classification. This system is recommended by the WHO for drug utilization studies. In the 
Anatomical Therapeutic Chemical classification system, the active substances of a 
medication are divided into different groups according to the functional system they have 
effects on besides the chemical properties of the medication. For example, in the 
Anatomical Therapeutic Chemical system captopril and enalapril which are inhibitors 
medications are given the code C09AA. 
To find the similarity based on medication classes, the drugs taken by both 
reference and compared patients will be converted to their drug classes. The converted list 
will have duplicated classes as a result of conversion of different drugs that belongs to the 
same drug class. Those duplicated classes will be removed from the converted lists. Then, 
the new two lists will be compared looking for the matches between them. The matched 
numbers will be used to find similarity using Simple Matching coefficients. 
Simple matching coefficient is useful when both positive and negative values 
carried equal information (symmetry). Here are the steps used in calculating the similarity: 
 
 
Step B.1: 
Convert the drug names of the reference patient to their corresponding drug classes. 
Step B.2: 
Convert the drug names of the compared patients to their corresponding drug classes. 
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Step B.3: 
Remove the duplicated classes resulted from the conversion of different Drugs that 
belong to the same Drug classes. 
Step B.4: 
The two new lists will be compared to find how many categories are in common using 
the following SMC: 
 
 
where, 
MT01 is the number of medication classes where reference patient has them and 
compared patient doesn’t. 
MT10 is the number of medication classes where reference patient doesn’t have them 
and compared patient has them. 
MT00 is the number of medication classes where both reference patient and compared 
patient have them. 
MT11 is the number of medication classes where both reference patient and compared 
patient don’t have them. 
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Example: 
Reference patient has 1 Drug class = {Statin} and the compared patient has 3 Drug 
Classes = {Statin, Analgesics (pain relievers), Antipyretics (fever reducers)}. 
The Drug Classes set is selected base on interested classes.  
In this example let’s assume the interested drug classes set is= {Statin, Inhibiters, 
analgesics}.  
Drug Class 
 
Statin Analgesics Inhibiters 
Reference patient Yes No No 
Compared patient Yes Yes No 
 
Then the SMC coefficients are calculated as shown: 
MT01 =0 
MT10 = 1 
MT00 = 1 
MT11=1 
Then Medication Class Similarity= (1+1)/ (0+1+1+1) =2/3. 
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Step C: Medication Quantity Similarity 
 
A large medication quantity can increases the possibility of adverse medication 
reactions and drug-drug interactions. It has also been associated with Toxicity which can 
be defined as "a consequence of administering a drug in quantities exceeding those capable 
of being physiologically managed by the host"[77].  Medication Quantity Similarity shows 
the similarity based on exposure amount of a medication class. In this dissertation, we are 
interested just in two drug classes which are Statin and Inhibitors. To find similarity based 
on medication quantity, medications of the reference patient is retrieved one by one and 
converted to the corresponding drug class using the Anatomical Therapeutic Chemical 
classification. Then the drug class will be examined whether it is one of the interested 
classes or not, i.e., Statin or Inhibitor. If yes, the doses of that medication will be extracted 
and added to the total dose of the class it belongs to (i.e., Statin drugs quantity or Inhibitor 
drugs quantity). Then the same procedure is done for the compared patient.  
       
The medication similarity will be calculated as shown: 
 
Step C.1: Retrieve a medication of the reference patient. 
Step C.2: Remove the drug dose from the drug name of that medication in order to be 
used. 
Step C.3: Convert the drug name to the corresponding Drug Classes using the Anatomical 
Therapeutic Chemical classification (see Step B of this section). 
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Step C.4: Examine the drug class if it is belonging to the interested classes, i.e., Statin or 
Inhibitor. If the drug class belongs to the interested classes, the drug dose of that 
medication will be used. 
Step C.5: Add the extracted drug dose to the total dose of the interested class it belongs to 
(i.e., Statin drugs quantity or Inhibitor drugs quantity). The total interested class doses are 
initialized to zero in the beginning. 
Step C.6: Repeat step 1 to 5 until processing all medications of the reference patient, 
Step C.7: Repeat step 1 to 6 for the compared patient. 
Step C.8: The Medication Quantity Similarity is calculated as the following: 
The Medication Quantity Similarity = 1   if: 
 
  (Statin drugs quantity >90 and Inhibitor drugs quantity >90)  
or 
  (Statin drugs quantity <90 and Inhibitor drugs quantity <90) 
      
The Medication Quantity Similarity = 0   if: 
 
 (Statin drugs quantity <90 and Inhibitor drugs quantity >90)  
 or 
 (Statin drugs quantity>90 and Inhibitor drugs quantity <90) 
 
106 
 
 
Threshold 90 is based on the fact that a drug-ADR pair is recognized if the potential 
ADR occurs at least once after one of the start dates of the drug within a certain period of 
time (i.e., 90 days). In that period of time the patient will take around 90 pills of 
medication. 
 
Step D: Total Medication Similarity  
Medication Similarity is calculated using the following tests: 
 
Test D-1: if the compared patient took medication classes that are totally different than 
the ones the reference patient then Medication Similarity is equal to zero without looking 
to other medication Similarities.  
No need to do Test 2 if Test 1 was satisfied. 
 
Test D-2: If the compared patient took some medication classes that are found in the 
reference patient medication list then Medication Similarity is calculated as the following: 
 
Medication Similarity= w1 x Medication Names Similarity + w3 x Medication Class 
Similarity + w2 x Medication Quantity Similarity. 
where w1+w2+w3=1. 
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    The selection of coefficients for combining sub similarities is experience dependent. 
Every coefficient depicts the weight of the corresponding sub-similarities. From the 
experience of the physician on our team the weights are w1=0.45, w2=0.25 and w3 = 0.30.  
 
3.3.6 Overall Similarity 
 
The similarity factors will be summed to give an overall weighted similarity 
between the referenced patient and the compared patient.  The overall similarity is 
computed as in: 
 
Overall Similarity = w1 x Temporal Association Similarity + w2 x Laboratory Tests 
Similarity + w3 x Symptoms and Morbidities Similarity + w4 x Age Similarity + w5 x 
Medication Similarity. 
where   w1 + w2 + w3 + w4 + w5 =1. 
 
The similarity scores are between 0 and 1 and a higher score represents a higher 
similarity. The selection of the coefficients for combining similarities is a crucial issue. 
Every coefficient depicts the weight of the corresponding sub factor similarity. These 
weights control the importance of the factors. In case of equally importance the weights 
will have the value 0.20. The weights can differ according to the physician point of view 
and depending on his experience. The weights can be adjusted base on the importance of 
the rule. 
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In general, if the experience-based similarity model classifies the similarity 
between x and y based on m parameters then the degree of similarity is defined as: 



m
i
iGlobal wiSimyxSim
1
*)(),(  
Where is Sim(i) is local similarity value for the parameter i ,and wi represent the 
corresponding weight of parameter i which represents the relative significance of that 
parameter.  Moreover, 
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iw  and SimGlobal(x,y) ∈[0,1] 
The final similarity score  between the reference patient and a patient being 
compared with, which  comes from different factors, is represented by “Degree of 
Similarity” whose values are labeled as ”Very High,” ”High,” ”Medium,” ”Low,” and 
”Very Low”. The similarity scores will be between 0 and 1 and a higher score represents a 
higher similarity. The similarity levels are shown below:  
 Level 1: Similarity score from 0.00 to 0.19 represents Very Low Similarity. 
 Level 2: Similarity score from 0.20 to 0.39 represents Low Similarity. 
 Level 3: Similarity score from 0.40 to 0.59   represents Moderate Similarity. 
 Level 4: Similarity score from 0.60 to 0.79 represents High Similarity. 
 Level 5: Similarity score from 0.80 to 1.0   represents Very High Similarity. 
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Those levels are decided by a bio-statistician and the physicians in our team. The 
compared patient is said to be matched with the reference patient to degree α, if S (C, C’) 
≥α where α ∈ [0, 1] is a similarity threshold chosen by the user.  
In the design of the Fuzzy Similar Patients Finder, we use the following settings: 
the Min-Max fuzzy inference and the centroid defuzzifier. Resulted Patients similarity vary 
in the strength based on (1) the experience of the agent; (2) the importance of the rules; and 
(3) presence or absence of some similarity rules; 
 
3.2 Experiments  
 
3.2.1 Experiment Settings 
 
The purpose of the simulation experiment is to examine whether the PAAs work 
together to find similar patients. To do that, I retrieved the patients who received at least 
one of the 8 drugs of interest in Veterans Affairs Medical Center in Detroit during the time 
period from January 1, 2005 to December 31, 2008. These 8 drugs represent the first 
targets in studying ADRs. These drugs are statin drugs and inhibitor drugs. A statin is a 
type of drug that helps patients lowers their cholesterol. An inhibitor is a type of drug that 
treats high blood pressure. The interested drugs include 6 statin drugs (i.e., rosuvastatin, 
atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) and 2 inhibitors 
(angiotensin-converting enzyme inhibitor) drugs (i.e., captopril, and enalapril).  
The retrieved patient data includes dispensing of drug, office visits, symptoms 
experienced, and laboratory testing. For each event certain details were obtained. The data 
for dispensing of drug includes name of the drug, quantity of the drug dispensed, dose of 
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the drug, drug start date, and the number of refills. The office visits data includes treatment 
regimens, treatment start dates and stop dates. The symptoms experienced data includes the 
symptoms appearance date, the symptoms ICD-9 codes and the ICD-9 code description.  
The laboratory testing data includes the names of the laboratory tests, laboratory test dates, 
laboratory test normal ranges and laboratory test results. The total number of retrieved 
patients was 20,000 (19,102 males and 898 females). Their average age was 68.0. This 
large number of patients was retrieved to be used in developing a detection methodology 
for ADRs. All the data was stored in a Microsoft Access database. The database had five 
tables, each of which contained one of the five types of information: (1) demographic data, 
(2) clinic visit data, (3) diagnostic data, (4) drug data, and (5) laboratory data. 
         
The experiment setting has four steps as shown below:  
 
Step 1: Selection of the patients 
The 20,000 patients are clustered into three groups. The 1st  group is for the patients 
who took only Inhibitor drugs and they are 3,414 patients. The 2rd group is for the patients 
who took both drug classes, Statin and Inhibitor, and it contains 7,711 patients. The 3rd  
group is for the patients who took only Statin drugs and it contains 8,875 patients. For the 
similarity evaluation experiments, we have selected randomly 199 patients out of the 
20,000 patients. We have selected 1% patients from each group. From the 1st, 2nd, 3rd group 
we have select 34, 77, and 88 patients respectively. The selection of 1% samples from each 
group was based on systematic sampling. The Systematic Sampling selects certain number 
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of members from a large population. To do the selection each member in the population 
(size N) will be assigned a number (from 1 to N) then a random number will be selected 
from this large population in order to be as a reference point to the systematic sampling 
process. Finally the selection of the members will be based on a fixed periodic interval of 
sampling.   
The nth” member is selected by dividing the total number of members in the general 
population by the desired number of members for the sampled population. For example, 
for selecting a random group of 88 patients from a population of 8,800 using systematic 
sampling, you would simply select every 100th person, since 8,800/88 = 100. Systematic 
sampling can be considered random, as long as the periodic sampling interval is 
determined beforehand and the sampling starting point is random [78]. 
 
Step 2: Distribution of the patients and the similarity rules among the PAAs 
I formed the agent system by implementing four PAAs. I divided the 199 patients 
among the agents as follows: PAA1 to PAA4 had 10 (5%), 29 (15%), 60(30%), and 100 
(50%) patients, respectively. By that I had PAAs with different levels of experiences. 
 The 200 patient was distributed to the 4 agents based on the following: 
 1st PAA will have 10 patients:    2 from 1st group, 4 from 2rd group, and 4 from 3rd 
group.  
 2nd PAA will have 29 patients: 4 from 1st group, 12 from 2rd group, and 13 from 3rd 
group.  
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 3rd PAA will have 60 patients:   11 from 1st group, 23 from 2rd group, and 26 from 
3rd group.  
 4th PAA will have 99 patients: 17 from 1st  group, 38 from 2rd group,  and 45 from 
3rd  group.  
 
By that I assure having low to high expert PAAs. 
       
Each PAA had part of the rules. The total number of the rules is 38. Some of these rules 
are key rules that all the agents will have. The key rules help PAAs to make a basic signal 
Similarity Finding (i.e., the rules involving calculating the Total Laboratory Similarity and 
the Global Similarity).  The remaining rules, which were randomly distributed, are 
classified into two classes: unique rules and overlapping rules. The numbers of each class 
that an agent has depended on the number of patients it had. The numbers of unique rules 
and overlapping rules shared between the PAAs are shown in Table 4.  
 
Table 4. Numbers of Unique and Overlapping Rules used by PAAs 
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Step 3: Select a random index as a reference case. 
    This index reference patient can be any patient from the 20,000 patients. In this 
experiment the reference patient has the following characteristics: 
1. Age 56. 
2.  Medications: Simvastatin and any of the ACIH drugs. 
3.  Has normal kidney function. 
4.  Has hypertension (ICD-9 401.9). 
5.  Has high cholesterol (ICD-9 272.0). 
 
Step 4: run the program and getting the result 
The process of starting the agents involved their registration with the JADE Main 
Container, which assigned a unique identifier to each PAA. The reference case was given 
to PAA1. Then, PAA1 will contact White Board in order to locate other agents available to 
assist in the case of interest. White Board will inform the PAA about the availability of 
other PAAs (i.e., PAA2, PAA3 and PAA4). The PAAs will then work with each other in 
order to update their detection rules. Finally, each PAA will evaluate its own patient’s 
cases and assign a similarity score for each of the cases. The evaluation outcome of each 
case will be forwarded to PAA1.  
 
3.2.2 Experiement Results 
 
PAA2, PAA3, and PAA4 provided PAA1 with the patient 29, 60 and 100 patients, 
respectively, with their similarity level. The similarity level belongs to one out of the five 
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levels, i.e., Level 1 = ‘Very Low Similarity,’ Level 2 = ‘Low Similarity,’ Level 3 = 
‘Moderate Similarity,’ Level 4 = ‘High Similarity.’ and Level 5=‘Very High Similarity.’ 
At the same time PAA1 evaluated its own patients, i.e., 10 patients. . The similarity levels 
assigned to each of the patient provided by the four PAAs are shown in Table 5.  
 
Table 5. Results of Similar Patients found by the 4-PAAs System. 
 
 
 
The multi-agent system took 6 hours to evaluate the 199 patients. From the 
software standpoint, the four agents collaboratively worked one another as designed. They 
updated their detection rules in proactive way and used the updated rules in evaluating the 
cases. 
Two physicians were participated in this study. They were asked to independently 
review each of the 199 patient cases and assigned a similarity level for the compared 
patients. In this evaluation, patient cases were retrieved one by one from Databases using a 
visual basic program done for that purpose. Figure 23 gives a scenario of the user interface. 
The top frame shows patients’ demographic information such as sex and age. For each 
patient, the other frames present his/her laboratory, pharmacy and diagnosis data. 
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Figure 23. User interface for showing patient data. 
 
The physician checked whether the patient is similar to the index patient or not.  
Then the physician assigned the similarity in a numerical score between 1 and 5 to show 
the strength of similarity. Where 1 = ‘Very Low Similarity,’ 2 = ‘Low Similarity,’ 3 = 
‘Moderate Similarity,’ 4 = ‘High Similarity.’ and 5=‘Very High Similarity.’ The similarity 
results generated by the multi-agent system and the two physicians (Physician 1 and 
physician 2) are shown in Table 6. 
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Table 6. Similarity Results Generated by the Multi-Agent System and Two Physicians 
(Physician 1 and Physician 2) 
 
Patient ID The System Decision Level 
Physician 1 
Decision 
Level 
Physician 2 
Decision 
Level 
Drug 
Group Agent 
1 4 4 4 Group 2 PAA 1 
2 5 5 5 Group 2 PAA 1 
3 3 5 3 Group 1 PAA 1 
4 5 5 5 Group 2 PAA 1 
5 4 3 4 Group 2 PAA 1 
6 4 3 4 Group 1 PAA 1 
7 3 2 2 Group 3 PAA 1 
8 2 2 2 Group 3 PAA 1 
9 5 5 5 Group 3 PAA 1 
10 4 5 5 Group 3 PAA 1 
11 5 5 5 Group 2 PAA 2 
12 4 4 4 Group 2 PAA 2 
13 4 4 4 Group 2 PAA 2 
14 4 3 3 Group 2 PAA 2 
15 4 4 5 Group 2 PAA 2 
16 4 4 4 Group 2 PAA 2 
17 5 5 5 Group 2 PAA 2 
18 4 3 3 Group 1 PAA 2 
19 5 5 5 Group 2 PAA 2 
20 3 3 3 Group 2 PAA 2 
21 1 1 1 Group 1 PAA 2 
22 5 5 5 Group 2 PAA 2 
23 5 5 5 Group 2 PAA 2 
24 2 2 2 Group 1 PAA 2 
25 5 5 5 Group 2 PAA 2 
26 3 4 3 Group 1 PAA 2 
27 3 3 3 Group 3 PAA 2 
28 5 5 5 Group 3 PAA 2 
29 4 4 4 Group 3 PAA 2 
30 3 3 3 Group 3 PAA 2 
31 5 5 5 Group 3 PAA 2 
32 4 4 4 Group 3 PAA 2 
33 4 3 3 Group 3 PAA 2 
34 2 2 2 Group 3 PAA 2 
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35 3 2 3 Group 3 PAA 2 
36 4 4 4 Group 3 PAA 2 
37 5 5 5 Group 3 PAA 2 
38 2 1 1 Group 3 PAA 2 
39 3 3 3 Group 3 PAA 2 
40 2 2 2 Group 1 PAA 3 
41 3 3 3 Group 1 PAA 3 
42 3 3 3 Group 3 PAA 3 
43 3 4 3 Group 3 PAA 3 
44 5 5 5 Group 3 PAA 3 
45 3 3 3 Group 3 PAA 3 
46 3 3 3 Group 3 PAA 3 
47 4 4 4 Group 2 PAA 3 
48 5 5 5 Group 3 PAA 3 
49 5 5 5 Group 2 PAA 3 
50 4 5 4 Group 2 PAA 3 
51 2 3 2 Group 1 PAA 3 
52 5 5 5 Group 2 PAA 3 
53 4 5 5 Group 2 PAA 3 
54 2 2 2 Group 1 PAA 3 
55 4 4 4 Group 2 PAA 3 
56 5 5 5 Group 2 PAA 3 
57 4 4 4 Group 1 PAA 3 
58 4 4 4 Group 2 PAA 3 
59 4 5 4 Group 2 PAA 3 
60 4 3 4 Group 1 PAA 3 
61 5 5 5 Group 2 PAA 3 
62 5 5 5 Group 2 PAA 3 
63 4 4 5 Group 1 PAA 3 
64 5 5 5 Group 2 PAA 3 
65 4 4 4 Group 2 PAA 3 
66 3 3 3 Group 1 PAA 3 
67 4 5 4 Group 2 PAA 3 
68 5 5 5 Group 2 PAA 3 
69 4 4 4 Group 3 PAA 3 
70 4 4 3 Group 1 PAA 3 
71 3 3 3 Group 2 PAA 3 
72 4 4 4 Group 3 PAA 3 
73 4 4 4 Group 2 PAA 3 
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74 2 2 2 Group 3 PAA 3 
75 3 3 3 Group 1 PAA 3 
76 3 3 3 Group 3 PAA 3 
77 5 5 5 Group 3 PAA 3 
78 2 2 2 Group 3 PAA 3 
79 3 3 2 Group 1 PAA 3 
80 3 3 3 Group 3 PAA 3 
81 3 4 3 Group 3 PAA 3 
82 4 4 4 Group 3 PAA 3 
83 3 1 3 Group 3 PAA 3 
84 4 4 4 Group 2 PAA 3 
85 4 5 4 Group 2 PAA 3 
86 5 5 4 Group 2 PAA 3 
87 5 5 5 Group 2 PAA 3 
88 5 5 5 Group 2 PAA 3 
89 3 3 3 Group 3 PAA 3 
90 2 3 2 Group 2 PAA 3 
91 3 3 3 Group 3 PAA 3 
92 3 3 3 Group 3 PAA 3 
93 5 4 4 Group 3 PAA 3 
94 3 3 3 Group 3 PAA 3 
95 4 4 4 Group 3 PAA 3 
96 4 3 4 Group 3 PAA 3 
97 4 4 4 Group 3 PAA 3 
98 4 4 4 Group 3 PAA 3 
99 4 4 4 Group 3 PAA 3 
100 3 3 4 Group 3 PAA 4 
101 2 2 2 Group 3 PAA 4 
102 4 5 3 Group 3 PAA 4 
103 4 4 4 Group 3 PAA 4 
104 3 3 3 Group 3 PAA 4 
105 3 3 3 Group 3 PAA 4 
106 3 3 3 Group 3 PAA 4 
107 2 2 2 Group 1 PAA 4 
108 4 3 3 Group 3 PAA 4 
109 4 4 4 Group 3 PAA 4 
110 4 3 4 Group 1 PAA 4 
111 1 1 1 Group 3 PAA 4 
112 5 5 5 Group 3 PAA 4 
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113 4 4 4 Group 3 PAA 4 
114 4 4 4 Group 3 PAA 4 
115 4 4 4 Group 3 PAA 4 
116 4 4 4 Group 2 PAA 4 
117 4 4 4 Group 1 PAA 4 
118 5 5 5 Group 3 PAA 4 
119 3 3 3 Group 3 PAA 4 
120 5 5 5 Group 3 PAA 4 
121 3 4 4 Group 3 PAA 4 
122 4 3 4 Group 3 PAA 4 
123 4 4 4 Group 3 PAA 4 
124 1 1 1 Group 3 PAA 4 
125 3 3 3 Group 3 PAA 4 
126 5 5 5 Group 3 PAA 4 
127 4 4 3 Group 3 PAA 4 
128 2 3 2 Group 3 PAA 4 
129 3 3 3 Group 3 PAA 4 
130 4 5 5 Group 3 PAA 4 
131 4 3 4 Group 3 PAA 4 
132 4 4 4 Group 2 PAA 4 
133 4 4 4 Group 2 PAA 4 
134 5 5 5 Group 2 PAA 4 
135 4 4 4 Group 2 PAA 4 
136 5 3 4 Group 2 PAA 4 
137 3 3 2 Group 1 PAA 4 
138 3 4 4 Group 2 PAA 4 
139 2 2 2 Group 3 PAA 4 
140 5 5 5 Group 2 PAA 4 
141 3 3 3 Group 3 PAA 4 
142 4 5 5 Group 2 PAA 4 
143 2 3 2 Group 1 PAA 4 
144 3 3 3 Group 3 PAA 4 
145 5 5 5 Group 2 PAA 4 
146 2 1 2 Group 3 PAA 4 
147 3 3 3 Group 3 PAA 4 
148 3 3 3 Group 3 PAA 4 
149 3 3 3 Group 1 PAA 4 
150 4 4 4 Group 3 PAA 4 
151 4 5 5 Group 3 PAA 4 
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152 2 2 2 Group 1 PAA 4 
153 3 3 3 Group 3 PAA 4 
154 4 4 4 Group 1 PAA 4 
155 5 5 5 Group 2 PAA 4 
156 5 5 5 Group 2 PAA 4 
157 4 4 4 Group 2 PAA 4 
158 4 4 4 Group 1 PAA 4 
159 2 2 2 Group 2 PAA 4 
160 5 5 5 Group 2 PAA 4 
161 4 4 4 Group 2 PAA 4 
162 2 3 2 Group 1 PAA 4 
163 4 4 4 Group 2 PAA 4 
164 4 4 4 Group 2 PAA 4 
165 5 5 5 Group 3 PAA 4 
166 5 5 5 Group 2 PAA 4 
167 3 3 3 Group 1 PAA 4 
168 5 5 5 Group 3 PAA 4 
169 4 4 4 Group 2 PAA 4 
170 4 4 4 Group 3 PAA 4 
171 4 4 4 Group 2 PAA 4 
172 4 5 5 Group 3 PAA 4 
173 2 2 2 Group 1 PAA 4 
174 5 5 5 Group 2 PAA 4 
175 3 3 3 Group 3 PAA 4 
176 5 5 5 Group 2 PAA 4 
177 3 3 3 Group 3 PAA 4 
178 5 5 5 Group 3 PAA 4 
179 5 5 5 Group 2 PAA 4 
180 2 2 2 Group 1 PAA 4 
181 5 5 5 Group 3 PAA 4 
182 5 5 5 Group 2 PAA 4 
183 4 4 4 Group 1 PAA 4 
184 4 4 4 Group 2 PAA 4 
185 3 3 3 Group 1 PAA 4 
186 5 5 5 Group 2 PAA 4 
187 4 4 4 Group 2 PAA 4 
188 2 2 2 Group 1 PAA 4 
189 5 4 4 Group 2 PAA 4 
190 4 5 5 Group 2 PAA 4 
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191 3 3 3 Group 1 PAA 4 
192 4 4 4 Group 2 PAA 4 
193 4 4 4 Group 2 PAA 4 
194 4 4 4 Group 2 PAA 4 
195 5 5 5 Group 2 PAA 4 
196 5 5 5 Group 2 PAA 4 
197 5 5 5 Group 2 PAA 4 
198 5 5 5 Group 2 PAA 4 
199 5 5 5 Group 2 PAA 4 
 
3.2.3 Analysis of the Result 
 
 
This section examines the agreement between the scores generated by the 
developed algorithm and those by each of the two physicians.  In this dissertation we used 
Kappa statistic to give the agreement between physicians and the system. A Kappa score 
ranges between 1 which shows full agreement and 0 which shows no agreement. In the 
literature there is no consensus about the interpretation of Kappa.  However [79] which is 
commonly used suggests that there is excellent agreement if the Kappa coefficient is  
greater than 0.75, poor agreement for Kappa coefficient less than 0.4, and fair to good 
agreement for kappa coefficient between 0.40 and 0.75 as shown in Table 7.   
 
Table 7. Interpretation of Kappa. 
 
Kappa Agreement 
<0.45 Poor Agreement 
0.45-0.75 Fair Agreement 
>0.75 Excellent Agreement 
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Table 8, 9 and 10 summarizes the number of matches between the decision of the system 
and the two physicians. 
 
Table 8.Confusion Matrix of System by Physician 1 
 
 Physician 1 
M
A
S 
Sy
st
em
 
Frequency 1 2 3 4 5 Total 
1 3 0 0 0 0 3 
2 2 15 5 0 0 22 
3 1 2 37 5 1 46 
4 0 0 11 52 12 75 
5 0 0 1 2 50 53 
Total 6 17 54 59 63 199 
 
 
Table 9. Confusion Matrix of System by Physician 2 
 Physician 2 
M
A
S 
Sy
st
em
 
Frequency 1 2 3 4 5 Total 
1 3 0 0 0 0 3 
2 1 21 0 0 0 22 
3 0 3 40 3 0 46 
4 0 0 7 59 9 75 
5 0 0 0 4 49 53 
Total 4 24 47 66 58 199 
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Table 10. Confusion Matrix of Physician 1 by Physician 2 
 Physician 2 
Ph
ys
ic
ia
n 
1 
Frequency 1 2 3 4 5 Total 
1 4 1 1 0 0 6 
2 0 16 1 0 0 17 
3 0 7 38 9 0 54 
4 0 0 5 52 2 59 
5 0 0 2 5 56 63 
Total 4 24 47 66 58 199 
 
The estimate of agreements is as follows: Kappa = 0.8014 for physician 1 and the 
developed system; Kappa = 0.8802 for physician 2 and the developed system; Kappa = 
0.8452 for physician 1 and physician 2. These coefficients suggest excellent agreement 
between the system and the physicians. The asymptotic standard error (ASE) is also 
computed, as well as 95% confidence bounds. Those values are computed using Weighted 
Kappa which considers disagreement close to the diagonals less heavily than disagreement 
further away from the diagonals. The simple Kappa is also provided.  The results of these 
two methods are shown in Table 11, 12 and 13. 
 
Table 11. Kappa Statistics between Physician 1 vs. MAS System. 
 
Kappa Statistics between Physician 1 vs. MAS 
System 
Statistic Value ASE 
95% Confidence 
Limits 
Simple Kappa 0.7114 0.0393 0.6344 0.7884 
Weighted 
Kappa 
0.8014 0.0292 0.7441 0.8586 
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Table 12. Kappa Statistics between Physician 2 vs. MAS System. 
 
Kappa Statistics between Physician 2 vs. MAS 
System 
Statistic Value ASE 
95% Confidence 
Limits 
Simple Kappa 0.8139 0.0335 0.7482 0.8796 
Weighted 
Kappa 
0.8802 0.0224 0.8363 0.9242 
 
Table 13. Kappa Statistics between Physician 1 vs. Physician 2 
Kappa Statistics between Physician 1 vs. 
Physician 2 
Statistic Value ASE 
95% Confidence 
Limits 
Simple Kappa 0.7742 0.0356 0.7043 0.8441 
Weighted 
Kappa 
0.8452 0.0263 0.7937 0.8967 
 
3.3 Summary 
 
I have developed a methodology that enables agents in a multi-agent 
environment to find similar patients. I implemented the system using JADE and FuzzyJess 
software packages and tested the system using four agents. Using real patient data, the 
results show that the agents effectively worked together to find similar patients. The 
experimental results indicate that the developed approach has excellent agreement with the 
decision of two physicians. 
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CHAPTER 4 
IDENTIFYING ADVERSE DRUG REACTION SIGNAL 
PAIRS BY THE MULTI-AGENT SYSTEM 
 
     Detecting ADR signal pairs is technically a complex problem. This is the case if 
we realistically assume that there does not exist a set of rules that are readily acceptable to 
all human experts (e.g., physicians, epidemiologists and pharmacists). The parameters used 
in identifying the signal pairs are really a vague, subjective measure rather than an 
objective measure. Furthermore, human experts often disagree one another owing to their 
knowledge and experiences and there is no “ground truth” to indicate which physician is 
right or wrong. Because of this and other limitations, current surveillance systems are not 
ideal for rapidly identifying rare unknown ADRs. A more effective system is needed as the 
electronic patient records become more and more easily accessible in various health 
organizations such as hospitals, medical centers and insurance companies. These data 
provide a new source of information that has great potentials to detect ADR signals much 
earlier.    
     In this chapter I presented the details a multi-agent system and the detection 
rules I recently developed [66]. The aim of the system is to help health organization 
systems achieve earlier identification of potential ADR signal pairs.  The PAA is equipped 
with the rule-based reasoning capability. More specifically, we have designed and 
developed a fuzzy inference engine for finding the causal relationship between a drug and 
an adverse reaction. This engine is called Fuzzy ADR Signal Pairs Detector. The Detector 
is a fuzzy rule-based system. 
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4.1 Cues for Drug Causality Assessment 
 
 My ADR signal pairs detection methodology is based on five cues: temporal 
association, rechallenge, dechallenge, abnormality in laboratory tests and other 
explanation. The cues represent the higher-level information that is obtained from the 
patients’ elementary data. The cues employed to evaluate the causality are abstracted from 
the description in [3] and summarized in  
Table 14. 
 
Table 14. Cues for Drug Causality Assessment. 
 
Cue Cue Type Cue Values Abstraction 
Method 
Temporal 
Association 
Fuzzy Likely, Probable, 
Possible, 
Unlikely 
Fuzzy Reasoning 
Dechallenge Fuzzy Likely, Probable, 
Possible, 
Unlikely 
Fuzzy Reasoning 
Rechallenge Fuzzy Likely, Possible, 
Unlikely 
Fuzzy Reasoning 
Abnormality in 
laboratory tests 
Fuzzy Low, Medium, 
High 
Fuzzy Reasoning 
Other 
explanations 
Nominal Yes, No Crisp Reasoning 
 
 Temporal Association is the cue that reflects the relationship between taking the 
drug and the appearance of a possible adverse event. What happens after the drug is 
stopped (Dechallenge) or re-initiated (Rechallenge) also provides important cues. 
Temporal association, rechallenge and dechallenge are all time-related. For a particular 
pair, their values can be extracted from a specific patient case using fuzzy sets and rules. 
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The Abnormality in Laboratory Tests is a fuzzy variable that is also extracted from 
patient’s laboratory test results. It describes the degree of the abnormality of a laboratory 
test. Other Explanations denotes alternative explanations by concurrent diseases or other 
drugs. The symptoms of an underlying disease or the one caused by another drug which is 
taken concurrently with the drug of interest cannot be differentiated from those of a 
potential ADR and thus the obtained cues (e.g., temporal association) values do not 
necessarily imply any degree of causality. 
To get some of those cues, we used the ICD-9-CM (International Classification of 
Diseases, Ninth Edition, Clinical Modification) and CPT codes (Physicians' Current 
Procedural Terminology), two widely used coding standards in the United States. Using 
these codes, every clinical condition of the patients, symptoms that appears one patients 
and any treatment required or done by a health provider has a unique code.  
      The detection rules that use the above cues were acquired through the joint 
efforts of the engineering and medical team members. There are a total of 52 detection 
rules. These rules will be distributed among the PAAs. This will be explained later in the 
experimental part.  In the real life each physician will provide his PAA with the 
preliminary detection rules based on his experience through Graphical User Interface and 
through the time PAA will learn new rules from other PAAs.  
      
4.1.1 Laboratory Test Abnormality  
 
As a first step the abnormality of laboratory tests are studied and analyzed. The 
abnormality of the laboratory tests is a very important factor in ADR signal pair detection. 
Most people with an adverse event in the early stages feel well and have no specific 
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findings on physical examination that would inform a health care provider. This places a 
large emphasis on laboratory test results that will be used to help diagnose patients and 
predict a patient’s response to certain medications. A signal pair is recognized if the 
potential ADR occurs after one of the start dates of the drugs within a certain period of 
time (i.e., 120 days). Lisinopril was selected as the target drug for this ADR signal 
generation study. Figure 24 shows that two pairs are found within one case. The laboratory 
tests occur after the first start date of Lisinopril. Thus a pair is formed between the drug 
and the closest occurrence of the elevation laboratory test. The potassium laboratory test 
which occurs before all the start dates of Lisinopril does not form a pair with the drug.  
 
Figure 24. Sample signal pairs within a patient case 
The patients’ database normally contains different refill dates. We can get the drug 
start date from those refill dates for diagnosing purposes based on the following critical: If 
the refill date is after 150 days of previous refill date, then this refill date will be 
considered as a new start date that should be used for signal pairs finding. Otherwise the 
refill date will not be considered as a new start date and it will not be used in signal pairs 
finding progress. Figure 25 shows an example of such situation. 
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Figure 25. Sample start dates out of refills dates. 
 
After a signal pair is found, its degree of association is assessed using fuzzy rules. 
Abnormalities of the laboratory tests are indicator of extensive problems in the patient. The 
more the elevation, the more the strength of the ADR signal.  
In this study, the hyperkalemia is the ADR of interest. Hyperkalemia is an 
excessive level of potassium in the bloodstream.    Potassium laboratory test reflects the 
functionality of the muscles, heart, and nerves. Potassium laboratory test will give an 
essential cue about this ADR. To get the degree of the abnormality of the potassium 
laboratory test, the laboratory result will be converted to its abnormality value. The 
abnormality value will be zero for a laboratory result in the normal ranges. For other 
values, the abnormality value will be calculated using fuzzy rules. The laboratory results 
will be the input to the system and the abnormality value will be the output.  Both the input 
and the output are fuzzy variables. There are three fuzzy sets for the input variable 
Potassium Laboratory Test Value- Low, Medium, and High (Figure 26), and three fuzzy 
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sets for the output variable Abnormality in Potassium Laboratory Test- Low, Medium, and 
High (Figure 27). Here are the rules:    
 If Potassium Laboratory Test Value is Low, then Abnormality in Potassium 
Laboratory Test is Low. 
 If Potassium Laboratory Test Value is Medium, then Abnormality in Potassium 
Laboratory Test is Medium. 
 If Potassium Laboratory Test Value is High, then Abnormality in Potassium 
Laboratory Test is High. 
 
 
Figure 26. Fuzzy sets for Potassium Laboratory Test Value 
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Figure 27. Fuzzy sets for Abnormality in Potassium Laboratory Test 
   
4.1.2 Laboratory Test Temporal Association 
 
Laboratory test temporal association is determined by the length of duration 
between a drug start date and a Laboratory result elevation occurrence date. Based on the 
experience of the physicians on the team, I define nine fuzzy rules of the Potassium 
Laboratory Test Temporal Association. Here are the rules: 
 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Short and Abnormality in Potassium Laboratory Test is High, then Potassium 
Laboratory Test Temporal Association is Likely. 
 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Short and the Abnormality in Potassium Laboratory Test is Medium, then 
Potassium Laboratory Test Temporal Association is Possible. 
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 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Short and Abnormality in Potassium Laboratory Test is Low, then Potassium 
Laboratory Test Temporal Association is Unlikely. 
 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Medium and Abnormality in Potassium Laboratory Test is High, then 
Potassium Laboratory Test Temporal Association is Likely. 
 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Medium and Abnormality in Potassium Laboratory Test is Medium, then 
Potassium Laboratory Test Temporal Association is Possible. 
 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Medium and Abnormality in Potassium Laboratory Test is Low, then Potassium 
Laboratory Test Temporal Association is Unlikely. 
 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Long and Abnormality in Potassium Laboratory Test is High, then Potassium 
Laboratory Test Temporal Association is Possible. 
 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Long and Abnormality in Potassium Laboratory Test is Medium, then 
Potassium Laboratory Test Temporal Association is Unlikely. 
133 
 
 
 If Time Duration between drug-taking and the appearance of the elevated potassium 
lab is Long and Abnormality in Potassium Laboratory Test is Low, then Potassium 
Laboratory Test Temporal Association is Unlikely. 
Both Potassium Time Duration and Potassium Laboratory Test Temporal 
Association are fuzzy variables characterized by triangular fuzzy sets. Figure 28 and 
Figure 29 show the fuzzy sets for both fuzzy variables, respectively. The universe course is 
set 15 to 130 days. That is, if the apparent ADR occurs between 15 days and 130 days after 
the drug start date, the pair is considered as having temporal association. 
 
 
Figure 28. Fuzzy sets for Potassium Laboratory Test Time Duration 
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Figure 29. Fuzzy sets for Potassium Laboratory Test Temporal Association 
       
 The above rules are used if the laboratory test is done between the drug start date 
and the drug stop date (if it is available) but if the laboratory test is done after both the drug 
start date and the drug stop date, another condition should be satisfied in order to use the 
above fuzzy rules. The laboratory test should be within certain period after the stop date, 
i.e., 60 days to be considered as a pair with the medication. This period was selected based 
on the opinion of the physician our team.  
Creatinine laboratory test is also used in calculating the ADR signal pair strength. 
This test measures the amount of Creatinine in blood. This test is used to evaluate kidney 
function. The rules used to determine Abnormality in Creatinine Laboratory Test are as 
follows, 
 If Creatinine Laboratory Test Value is Low, then Abnormality in Creatinine 
Laboratory Test is Low. 
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 If Creatinine Laboratory Test Value is High, then Abnormality in Creatinine 
Laboratory Test is High. 
 
The two fuzzy variables used to determine Abnormality in Creatinine Laboratory 
Test are characterized by bell fuzzy sets (Figure 30 and Figure 31). 
  
 
Figure 30. Fuzzy sets for Creatinine Laboratory Test Value. 
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Figure 31. Fuzzy sets for Abnormality in Creatinine Laboratory Test. 
 
The Creatinine Temporal Association is calculated in the same way as the 
Potassium Temporal Association.    Based on the experience of the physicians on the team, 
I define six fuzzy rules of the Creatinine Laboratory Temporal Association. Here are the 
rules: 
 If Time Duration between drug-taking and the appearance of the elevated Creatinine 
lab is Short and Abnormality in Potassium Laboratory Test is High, then Creatinine 
Laboratory Test Temporal Association is Likely. 
 If Time Duration between drug-taking and the appearance of the elevated Creatinine 
lab is Short and Abnormality in Creatinine Laboratory Test is Low, then Creatinine 
Laboratory Test Temporal Association is Possible. 
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 If Time Duration between drug-taking and the appearance of the elevated Creatinine 
lab is Medium and Abnormality in Creatinine Laboratory Test is High, then 
Creatinine Laboratory Test Temporal Association is Likely. 
 If Time Duration between drug-taking and the appearance of the elevated Creatinine 
lab is Medium and Abnormality in Creatinine Laboratory Test is Low, then 
Creatinine Laboratory Test Temporal Association is Possible 
 If Time Duration between drug-taking and the appearance of the elevated Creatinine 
lab is Long and Abnormality in P Creatinine Laboratory Test is High, then Creatinine 
Laboratory Test Temporal Association is Possible. 
 If Time Duration between drug-taking and the appearance of the elevated Creatinine 
lab is Long and Abnormality in Creatinine Laboratory Test is Low, then Creatinine 
Laboratory Test Temporal Association is Unlikely. 
       
     Both Creatinine Time Duration and Creatinine Laboratory Test Temporal Association 
are fuzzy variables characterized by triangular fuzzy sets. Figure 32 and Figure 33 show 
the fuzzy sets for both fuzzy variables, respectively.  
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Figure 32. Fuzzy sets for Creatinine Laboratory Test Time Duration. 
 
 
Figure 33. Fuzzy sets for Creatinine Laboratory Test Temporal Association. 
 
The strength of Total Laboratory Test Temporal Association is founded using ten 
fuzzy rules. Here are the rules: 
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 If Potassium Laboratory Test Temporal Association is Likely and Creatinine 
Laboratory Test Temporal Association is available and it is Likely, then Total 
Laboratory Test Temporal Association is Likely. 
 If Potassium Laboratory Test Temporal Association is Likely and Creatinine 
Laboratory Test Temporal Association is available and it is Possible, then Total 
Laboratory Test Temporal Association is Probable. 
 If Potassium Laboratory Test Temporal Association is Likely and Creatinine 
Laboratory Test Temporal Association is available and it is Unlikely, then Total 
Laboratory Test Temporal Association is Possible. 
 If Potassium Laboratory Test Temporal Association is Possible and Creatinine 
Laboratory Test Temporal Association is available and it is Likely, then Total 
Laboratory Test Temporal Association is Likely. 
 If Potassium Laboratory Test Temporal Association is Possible and Creatinine 
Laboratory Test Temporal Association is available and it is Possible, then Total 
Laboratory Test Temporal Association is Probable. 
 If Potassium Laboratory Test Temporal Association is Possible and Creatinine 
Laboratory Test Temporal Association is available and it is Unlikely, then Total 
Laboratory Test Temporal Association is Possible. 
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 If Potassium Laboratory Test Temporal Association is Unlikely and Creatinine 
Laboratory Test Temporal Association is available and it is Likely, then Total 
Laboratory Test Temporal Association is Probable. 
 If Potassium Laboratory Test Temporal Association is Unlikely and Creatinine 
Laboratory Test Temporal Association is available and it is Possible, then Total 
Laboratory Temporal Association is Possible. 
 If Potassium Laboratory Test Temporal Association is Unlikely and Creatinine 
Laboratory Test Temporal Association is available and it is Unlikely, then Total 
Laboratory Test Temporal Association is Unlikely. 
 If Creatinine Laboratory Test Temporal Association is unavailable, then Total 
Laboratory Test Temporal Association is equal to Potassium Laboratory Test 
Temporal Association. 
 
The total Laboratory Test Temporal Association which is composed of Potassium 
laboratory test and Creatinine laboratory test is a fuzzy variable represented by four 
Gaussian membership functions categorized as ”Likely,” ”Probable,” ”Possible,” and 
”Unlikely” as shown in Figure 34.  
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Figure 34. Fuzzy sets for Total Laboratory Test Temporal Association. 
 
If the Creatinine laboratory test is elevated before and after taking the suspect 
medication, then the elevation of the Creatinine laboratory test will be considered as 
another explanation for the elevated potassium and this will decreases the ADR causality 
by certain value specified by the agent and his physician. 
 
 4.1.3 Medication Dechallenge  
 
     Medication Dechallenge refers to the relationship between discontinuity of the 
drug and abatement of the apparent ADR. Dechallenge is a fuzzy variable characterized by 
triangular fuzzy sets labeled as ”Unlikely,” ”Possible,” ”Probable,” and ”Likely” as shown 
in Figure 35. 
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Figure 35. Fuzzy sets for Dechallenge 
 
We cannot directly evaluate dechallenge of a pair since the drug stop date is usually 
unavailable in electronic health databases. However, we can indirectly assess the existence 
of dechallenge of a pair if a symptom occurs after the drug start date and another drug in 
the same class was prescribed after the appearance of the symptom. This is because the 
physicians often stop a drug and prescribe another drug in the same class to avoid apparent 
adverse effect found on a patient. 
Also, if the temporal association is Unlikely, then Dechallenge is Unlikely. In some 
cases the patient stops taking the drug for a period greater than 150 days then the stop date 
can be considered as the previous start date plus the number of days the patient took that 
medication. In such cases six fuzzy rules will be applied to get the strength of dechallenge. 
Here are the rules: 
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 If Time Duration between stopping the drug and the abatement of the apparent 
symptoms is Very Small, then Dechallenge is Likely. 
 If Time Duration between stopping the drug and the abatement of the apparent 
symptoms is Small, then Dechallenge is Probable. 
 If the Time Duration between stopping the drug and the abatement of the symptoms 
is Large then Dechallenge is Possible. 
 If the Time Duration between stopping the drug and the abatement of the symptoms 
is Very Large then Dechallenge is Unlikely. 
 If the reaction does not abate after withdrawal of drug then Dechallenge is Unlikely. 
 If the reactions occurred again after the drug was discontinued then Dechallenge is 
Unlikely. 
    Time Duration between stopping the drug and the abatement of the symptoms is a 
fuzzy variable represented by triangular membership functions (Figure 36). 
 
144 
 
 
 
Figure 36. Fuzzy sets for Time Duration between stopping drug and symptom abatement 
 
 
4.1.4  Medication Rechallenge 
 
Medication Rechallenge depicts the relationship between re-introduction of the 
drug discontinued before and recurrence of an ADR. Rechallenge is determined by the 
temporal associations of the two consecutive occurrences of the same pair one after taking 
the medication and the other one after the reintroduction of the medication. Let Temporal 
Association of time t1 and Temporal Association of time t2 represent the two temporal 
associations, respectively. Then the following fuzzy rules are used to assess the value of 
the Rechallenge of a pair. 
 If Temporal Association of time t1 is Likely and Temporal Association of time t2 is 
Likely Then Rechallenge is Likely. 
 If Temporal Association of time t1 1 is Likely and Temporal Association of time t2 is 
Possible Then Rechallenge is Likely. 
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 If Temporal Association of time t1 is Likely and Temporal Association of time t2 is 
Unlikely Then Rechallenge is Possible. 
 If Temporal Association of time t1 is Possible and Temporal Association of time t2 is 
Likely Then Rechallenge is Likely. 
 If Temporal Association of time t1 is Possible and Temporal Association of time t2 is 
Possible Then Rechallenge is Possible. 
 If Temporal Association of time t1 is Possible and Temporal Association of time t2 is 
Unlikely Then Rechallenge is Possible. 
 If Temporal Association of time t1 is Unlikely and Temporal Association of time t2 is 
Likely Then Rechallenge is possible. 
 If Temporal Association of time t1 is Unlikely and Temporal Association of time t2 is 
Possible Then Rechallenge is Possible. 
 If Temporal Association of time t1 is Unlikely and Temporal Association of time t2 is 
Unlikely Then Rechallenge is Unlikely. 
Both Temporal Association and Rechallenge are fuzzy variables. The Temporal 
Association is defined in Figure 29. Rechallenge is fuzzified by three fuzzy sets Likely, 
Possible and Unlikely (Figure 37) 
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Figure 37. Fuzzy sets for Rechallenge. 
 
4.1.5 Causality Assessment     
 
 
Causality assessment determines the likelihood that a drug causes a suspected 
ADR. The strength of the Causality assessment between the drug and an adverse effect is 
called Degree of Causality. The Degree of Causality is calculated as a linear combination 
of the effect of the cues. The aggregated Degree of Causality is calculated as the following: 
 
Degree of Causality = w1 x Laboratory Temporal Association + w2 x Dechallenge + w3 x 
Rechallange  
         where   w1 + w2 + w3 =1 
     
The selection of the coefficients for combining similarities is a crucial issue. The 
weights control the importance of the corresponding cues. In case of equally importance, 
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the weights will have the value 1/3. The causality scores are between 0 and 1 and a higher 
score represents a higher similarity. 
   
4.2 Other Factors in Causality Assessment 
 
Degree of Causality can be affected by other reasons that can lead to the same 
apparent ADR symptom. This includes two factors - other medications and other ICD-9 
codes.  
 
4.2.1 Other Medications 
 
Excess potassium in the bloodstream can result from certain medications. Examples 
of such medications are: 
 Potassium supplements. 
 Spironolactone  (diuretic drug group). 
 Triamterene (diuretic drug group). 
 Amiloride (Diuretic drug group). 
 Eplerenone. 
 Pentamidine (antimicrobial drug group). 
 Trimethoprim (trimethoprim/sulfa – antimicrobial drug group). 
 Ketoconazole (antimicrobial drug group). 
 NSAIDS – non-steroidal anti-inflamatory agents. 
 Heparin. 
 Cyclosporin. 
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Having such medications in the patient database will lower the strength of Degree of 
Causality.  
     The reduction is based on the following rules: 
 If one medication was founded beside the interested drug then Degree of Causality 
will be lowered  by 0.5 
 If two medications were founded beside the interested drug then Degree of Causality 
will be lowered  by 0.25 
 If more than two medications were founded, no ADR signal pair will be considered. 
4.2.2 Concurrent Diseases 
 
Diseases of the kidneys or adrenal glands will affect the strength of Degree of 
Causality. Diseases are found in patients Databases as ICD-9 codes so the existence of 
certain ICD-9 codes will affect the Degree of Causality. 
The ICD-9 provides codes to classify diseases and a wide variety of signs, 
symptoms, abnormal findings, complaints, social circumstances, and external causes of 
injury or disease. For example, if a patient is diagnosed with Hepatitis C, it will be given 
the ICD-9 code (070.51). The ICD-9 codes will stay in the patient databases no matter the 
diagnosis is for something acute or chronic. 
Since different ICD-9 codes may represent the same (or similar) diagnoses, we also 
clustered them into a manageable number of categories based on the Clinical 
Classifications System (CCS). Searching patient CCS codes can lead to Other Explanation. 
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For example most cases of hyperkalemia are caused by disorders that reduce the kidney’s 
ability to get rid of potassium. This may result from disorders such as acute kidney failure 
(CCS code 157) or chronic kidney failure (CCS code 158). Having such a CCS category 
will reduce the Degree of Causality by 0.50. This is because such a CCS Category will 
offer another explanation of the manifest symptoms. Here are the rules of score reduction: 
 If one CCS code that gives other explanation to the suspect ADR appears in the 
patient records then the Degree of Causality will be reduced by 0.5. 
 If two CCS codes that give other explanations to the suspect ADR appears in the 
patient records then the Degree of Causality will be reduced by 0.75. 
 If more than two CCS codes that give other explanation to the suspect ADR appears 
in the patient records then the Degree of Causality will be reduced to 0 (meaning no 
signal pairs found). 
 
Some CCS categories such as hyperkalemia (CCS code 55) will support and 
increase the Degree of Causality if it has been reported after taking the medication of this 
study. However this category shouldn’t appear prior to medication-taking. The increase of 
the Degree of Causality is based on CCS Temporal Association value which describes the 
time duration between taking the drug and the appearance of the symptoms (i.e., the ICD-9 
code) which is CCS Time Duration. There are four triangular fuzzy sets for the variable 
CCS Time Duration – Very Short, Short, Long and Very Long and four triangular fuzzy 
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sets to define the variable CCS Temporal Association: Likely, Probable, Possible and 
Unlikely.  
Figure 38 and Figure 39 show the fuzzy sets for CCS Time Duration and CCS 
Temporal Association, respectively. 
 
 
Figure 38. Fuzzy sets for CCS Time Duration. 
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Figure 39. Fuzzy sets for CCS Temporal Association. 
 
CCS Temporal Association will be calculated using four fuzzy rules. Here are the rules: 
      If the Time Duration between taking the drug and the appearance of the CCS code is 
Very Short then CCS Temporal Association is Likely. 
 If the Time Duration between taking the drug and the appearance of the CCS code is 
Short then CCS Temporal Association is Probable 
 If the Time Duration between taking the drug and the appearance of CCS code is 
Long then CCS Temporal Association is Possible. 
 If the Time Duration between taken the drug and the appearance of CCS code is 
Very Long then CCS Temporal Association is Unlikely. 
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 The defuzzified CCS Temporal Association value will be weighted by 0.5 in order 
to get the increment value of the Degree of Causality. 
The CCS categories that support the ADR signal strength should be reported after 
taking the studied medication. If it has been reported before the start date of the 
medication, then it will not support the strength of ADR signal anymore. It will rather 
decrease the ADR Signal by 0.25 because such categories will be considered as other 
explanation. 
 Figure 40  shows an example of such situation. The patient took the medication 
LISIOPRIL on 5/16/2008 and the potassium laboratory test was elevated on 06/05/2008 
while the Hyperkalemia, ICD-9 267.7, was reported on 01/29/2007. This finding will 
decrease Degree of Causality of that patient by 0.25 because this gives indication that the 
elevation could be from a reason other than the medication. 
 
 
Figure 40. Patient Case for Other Explanation Scenario. 
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In all cases the “Degree of Causality” value should stay between 0 and 1. In case 
the value is greater than 1 or less than 0 then it will rounded to 1 or 0 respectively. 
Patient cases vary in the strength of the possible causal association between the 
drug and an event based on (1) the temporal association; (2) evidence for dechallenge; (3) 
evidence for rechallenge; (4) presence or absence of an alternative explanation for the 
adverse event; and (5) presence or absence of abnormality in the laboratory tests.  
The final “Degree of Causality” score is represented by 4 levels whose values are 
labeled as, Level 1 = “No Signal Pairs,” Level 2 = “Unlikely,” Level 3 = “Possible,” and 
Level 4=“Likely.”   
 Level 1: “Degree of Causality” score from 0.00 to 0.25 represents No Signal Pairs. 
 Level 2: “Degree of Causality” score from 0.25 to 0.50 represents Unlikely. 
 Level 3: “Degree of Causality” score from 0.50 to 0.75   represents Possible. 
 Level 4: “Degree of Causality” score from 0.75 to 1.00 represents Likely. 
 
4.3 Experiments  
 
4.3.1 Experiment Settings 
 
The purpose of the simulation experiment is to preliminarily examine whether the 
PAAs work together in identifying ADR signal pairs. A suspect case will be given to one 
of the PAAs (i.e., PAA1). Then, PAA1 will contact the White Board in order to locate 
other agents available to assist in the case of interest. The White Board will inform the 
PAA about the availability of other PAAs (i.e., PAA2, PAA3 and PAA4). The PAAs will 
then work with each other in order to update their detection rules. Finally, each PAA will 
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evaluate its own patient’s cases and assign causal link strengths for them. The evaluation 
outcome of each case will be forwarded to PAA1. To evaluate the effectiveness of the 
developed system, we retrieved the electronic data of all patients who received at least one 
of the 11 drugs of interest in the Veterans Affairs Medical Center in Detroit during the 
time period from January 1, 2005 to December 31, 2008. The interested drugs include 6 
statin drugs (i.e., rosuvastatin, atorvastatin, fluvastatin, lovastatin, pravastatin, and 
simvastatin) and 5 inhibitors (angiotensin-converting enzyme inhibitor) drugs (i.e., 
benazepril, captopril, enalapril, fosinopril and lisinopril). Statin is a type of drug that helps 
patients improves their cholesterol level. Inhibitors are a type of drug that treats high blood 
pressure. Event data such as demographic data, patient visit data, diagnostic data, drug-
related data, and laboratory data was retrieved for all the patients. For each event certain 
details were obtained. For example, the data for dispensing of drug includes name of the 
drug, subject ID, quantity of the drug dispensed, dose of the drug, drug start date, drug 
schedule, and the number of refills. The total number of retrieved patients was 20,000 
(19,102 males and 898 females). Their average age was 68.0. All the data was stored in a 
2007 Microsoft Access database. As mentioned above, we selected Lisinopril as the target 
drug for this ADR signal study. This reduced the number of patients to 10,048.  
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The experiment setting has three steps as shown below:  
 
Step 1: Selection of the patients 
Since I need two physicians to evaluate the multi-agent intelligent system 
performance .we need to minimize the number of patients to a certain acceptable number 
since the evaluation of such high number will take long time from them. The biostatistician 
suggested selecting randomly 2% out of the 10.048 patient. We cannot apply the 
systematic sampling we used in finding similar patient here since we are dealing evaluating 
a rare event. Otherwise we may miss one of the levels (i.e. Level 4) since the appearance 
probability of such level in real medical life is around 0.2%. The used way to get the 2% 
out of the 10,048 patients is by evaluating the 10.048 using a centralized system developed 
by me that contains all the detection rules. The resulting causal link strengths provided by 
the centralized system are shown in Table 15. A biostatistician in the team suggests 
sampling each level by certain percentage as shown in Table 15. This will produce 194 
patients randomly selected from each Level. Some levels the biostatistician suggested a 
100% sampling which means use all the patients in that level. This sampling is needed 
since this level has the highest association between the drug and the potential adverse 
events which is rear in real life data (i.e. 0.1 to 0.2 percent).  
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Table 15. Number of patients provided by the centralized system, Sample Percentages and 
Number of Patients after sampling in each level. 
 
Level Number of 
Patients 
Sample 
Percentage
Number of 
Patients After 
Sampling 
Level 1 9492 %0.8 75 
Level 2 276 %12 33 
Level 3 254 %24 60 
Level 4 26 %100 26 
Total Number of 
Patients 10048 
N/A 194 
 
Figure 41 shows the centralized methodology for Identifying ADR signal pairs. 
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Figure 41. The Centralized Methodology for Identifying ADR Signal Pairs. 
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Step 2: Distribution of the patients and the detection rules among the PAAs 
 
I formed the agent system by implementing four PAAs (I choose four because it is 
representative enough while computing time is still reasonable). I divided the 194 patients 
randomly among the agents as follows: PAA1 to PAA4 had 10 (5%), 29 (15%), 58 (30%), 
and 97 (50%) patients, respectively. Having different number of patients for each PAA will 
lead to PAA with different levels of experiences as in real life problem. Each PAA had part 
of the rules. The total number of the rules is 52. Some of these rules are key rules that all 
the agents will have. In this experiment the key rules are made up of Potassium Temporal 
Association rules and Potassium Test Abnormality. The remaining fuzzy rules, which were 
randomly distributed, are classified into two classes: unique rules and overlapping rules. 
The numbers of each class that an agent has depended on the number of patients it had. 
The numbers of unique rules and overlapping rules shared between the PAAs are shown in 
Table 16.  
 
Table 16. Numbers of Unique and Overlapping Rules used by PAAs. 
 
       
Agents 
Number of 
Unique Rules 
Number of 
Overlapped 
Rules 
Total Number 
of Rules 
PAA1 6 12 18 
PAA2 8 12 20 
PAA3 10 12 22 
PAA4 16 12 28 
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Step 3: run the program and send a suspect signal pairs to PAA1 and getting the 
result 
 
The process of starting the agents involved their registration with the JADE Main 
Container, which assigned a unique name to each PAA. Then, a suspect signal pair case 
was sent by PAA1 to the other three PAAs. The case was “patient has elevated potassium 
laboratory test result while taking Lisinopril”. Then, PAA1 will contact White Board in 
order to locate other PAAs available to assist in the suspect signal pairs. White Board will 
inform the PAA about the availability of other PAAs (i.e., PAA2, PAA3 and PAA4). The 
PAAs will then work with each other in order to update their detection rules. Finally, each 
PAA will evaluate its own patient’s cases and assign a causality score for each of the cases. 
The evaluation outcome of each case will be forwarded to PAA1 and then his physician.  
 
4.3.2 Experiment Results 
 
 
The four PAAs worked with each other and produced a Degree of Causality for 
each one of the patients. The causal link strength of each patient is assigned as a level that 
belongs to one of the four levels, i.e., Level 1 = “No Signal Pairs,” Level 2 = “Unlikely,”  
Level 3 = “Possible,” and Level 4=“Likely.”  The resulting causal link strengths provided 
by the four PAAs are shown in Table 17.  
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Table 17. Results of Causal Link Founded by the 4-PAAs System. 
 
    Number 
of patients 
 
 
Agents 
Category 
“Likely” 
Level 4 
Category 
“Possible” 
Level 3 
Category 
“Unlikely” 
Level 2 
Category 
“No Signal 
Pairs” 
Level 1 
Total 
Number 
of 
Patients 
PAA1 0 3 2 5 10 
PAA2 4 5 5 15 29 
PAA3 7 15 11 25 58 
PAA4 16 38 17 26 97 
Total 
number of 
patients 
27 61 35 71 194 
 
As shown in the table, the total number of patients in the categories “Likely”, “ 
“Possible”, “Unlikely”, and “No Signal Pairs” was found to be 27, 61, 35, and 71, 
respectively.  For example PAA2, PAA3, and PAA4 provided PAA1 with 4, 7 and 16 
“Likely” patients, respectively. At the same time PAA1 searched its patients’ database and 
it found one patient with “Likely” decision in its database. The multi-agent system took 9 
hours to evaluate the 194 patients. From the software standpoint, the four agents 
collaboratively worked one another as designed. They updated their detection rules in 
proactive way and used the updated rules in evaluating the cases. Two physicians were 
participated in this study. They were asked to independently review each of the 194 patient 
cases and assigned a causality level. In this evaluation, patient cases were retrieved one by 
one from Databases using a visual basic program done for that purpose. 
The physician checked the patient and assigned the causality score in a numerical 
score between 1 and 4 to show the strength of similarity. Where 1 = ‘No Signal Pairs,’ 2 = 
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‘Unlikely,’ 3 = ‘Possible,’ and 4=‘Likely.’ The causality results generated by the multi-
agent system and the two physicians (Physician 1 and physician 2) are shown in Table 18. 
 
Table 18. Degree of Causality Results Generated by the Multi-Agent System and the 
Decisions of the Two Physicians (Physician 1 and Physician 2) 
 
Patient ID 
The System 
Decision  
Physician 1 
Decision  
Physician 2 
Decision  
1 1 1 1 
2 3 4 3 
3 2 1 3 
4 3 3 2 
5 1 1 1 
6 1 1 1 
7 3 3 3 
8 1 1 1 
9 2 1 2 
10 1 1 1 
11 1 1 2 
12 1 1 2 
13 1 1 2 
14 1 1 2 
15 1 1 1 
16 2 2 3 
17 1 1 1 
18 1 1 1 
19 3 3 3 
20 1 1 2 
21 1 1 1 
22 3 3 3 
23 1 1 1 
24 3 1 3 
25 1 1 1 
26 1 1 2 
27 1 1 2 
28 2 2 2 
29 3 3 4 
30 1 1 1 
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31 1 1 1 
32 1 1 1 
33 1 1 1 
34 1 1 1 
35 2 2 3 
36 2 2 2 
37 2 2 2 
38 1 1 1 
39 1 1 1 
40 2 3 2 
41 1 1 1 
42 1 1 1 
43 3 1 2 
44 1 1 1 
45 1 1 1 
46 1 1 1 
47 1 1 1 
48 1 1 1 
49 3 3 3 
50 1 1 1 
51 3 3 2 
52 2 1 2 
53 1 1 1 
54 2 1 3 
55 1 1 1 
56 1 1 1 
57 1 1 1 
58 1 1 1 
59 1 1 1 
60 1 1 1 
61 1 1 1 
62 2 1 2 
63 1 1 1 
64 2 1 2 
65 2 1 2 
66 1 1 1 
67 1 1 1 
68 2 3 2 
69 2 1 2 
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70 1 1 1 
71 1 1 1 
72 2 1 3 
73 1 1 1 
74 1 1 2 
75 1 1 1 
76 1 1 1 
77 1 1 1 
78 1 1 1 
79 4 4 4 
80 1 1 1 
81 1 1 1 
82 2 3 4 
83 1 1 1 
84 1 1 1 
85 1 1 1 
86 1 1 1 
87 1 1 1 
88 1 1 1 
89 1 1 1 
90 1 1 1 
91 1 1 1 
92 1 1 1 
93 1 1 2 
94 2 1 3 
95 3 3 3 
96 3 3 3 
97 3 3 3 
98 1 1 1 
99 3 3 3 
100 2 3 2 
101 3 3 3 
102 3 3 2 
103 3 3 3 
104 3 3 3 
105 4 3 4 
106 2 1 2 
107 3 3 2 
108 3 3 3 
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109 3 3 3 
110 3 3 3 
111 3 3 2 
112 4 4 4 
113 2 1 2 
114 2 3 2 
115 3 3 2 
116 4 3 4 
117 4 4 4 
118 2 2 3 
119 3 3 3 
120 4 3 4 
121 4 4 4 
122 2 2 2 
123 3 3 3 
124 1 1 1 
125 2 2 2 
126 2 2 2 
127 3 3 3 
128 3 3 2 
129 3 3 3 
130 3 3 3 
131 4 4 4 
132 4 3 3 
133 3 3 3 
134 3 3 3 
135 3 3 3 
136 3 3 3 
137 2 3 2 
138 3 3 3 
139 3 3 3 
140 3 3 3 
141 3 3 3 
142 4 4 4 
143 3 3 3 
144 4 4 4 
145 1 1 1 
146 3 3 3 
147 3 3 3 
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148 4 4 4 
149 3 3 3 
150 3 3 3 
151 1 1 1 
152 3 3 3 
153 3 3 3 
154 4 4 4 
155 3 3 3 
156 2 2 3 
157 4 4 4 
158 2 3 2 
159 3 3 4 
160 3 3 3 
161 2 3 2 
162 4 4 4 
163 2 1 3 
164 4 4 4 
165 3 4 4 
166 4 4 3 
167 4 4 3 
168 2 2 3 
169 3 4 3 
170 3 3 3 
171 3 4 4 
172 4 4 3 
173 3 3 3 
174 4 4 4 
175 1 1 1 
176 2 3 2 
177 3 3 3 
178 2 1 2 
179 1 1 1 
180 2 3 2 
181 3 3 2 
182 3 3 3 
183 3 3 3 
184 4 4 4 
185 4 4 4 
186 4 4 4 
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187 3 3 2 
188 3 3 4 
189 3 4 3 
190 4 4 4 
191 4 4 4 
192 4 4 4 
193 4 4 4 
194 3 3 3 
 
 
4.3.3  Analysis of the Results 
 
 
In this section will examine the agreement between the causality levels generated 
by the developed algorithm and those by each of the two physicians.  I have utilized Kappa 
statistic to estimate the levels of agreement. The Kappa coefficient as mentioned before is 
an estimate of the agreement between two raters. Table 19, 20 and 21 summarizes the 
number of matches between the decision of the system and the two physicians. 
 
Table 19.Confusion Matrix of System by Physician 1. 
 
 Physician 1 
M
A
S 
Sy
st
em
 
Frequency 1 2 3 4 Total 
1 71 0 0 0 71 
2 14 11 10 0 35 
3 2 0 54 5 61 
4 0 0 4 23 27 
Total 87 11 68 28 194 
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Table 20. Confusion Matrix of System by Physician 2. 
 Physician 2 
M
A
S 
Sy
st
em
 
Frequency 1 2 3 4 Total
1 62 9 0 0 71 
2 0 24 10 1 35 
3 0 10 46 5 61 
4 0 0 4 23 27 
Total 62 43 60 29 194 
 
Table 21. Confusion Matrix of Physician 1 by Physician 2. 
 Physician 2 
Ph
ys
ic
ia
n 
1 
Frequency 1 2 3 4 Total 
1 62 19 6 0 87 
2 0 6 5 0 11 
3 0 18 43 7 68 
4 0 0 6 22 28 
Total 62 43 60 29 194 
 
The estimate of agreements is as follows: Kappa = 0.8448 for physician 1 and the 
developed system; Kappa = 0.8274 for physician 2 and the developed system; Kappa = 
0.7196 for physician 1 and physician 2. These coefficients suggest excellent agreement 
between the system and the physicians. The asymptotic standard error (ASE) is also 
computed, as well as 95% confidence bounds. Those values are computed using Weighted 
Kappa which considers disagreement close to the diagonals less heavily than disagreement 
further away from the diagonals. The simple Kappa is also provided.  The results of these 
two methods are shown in Table 22, 23, and 24. 
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Table 22. Kappa Statistics between Physician 1 vs. MAS System. 
 
Kappa Statistics between Physician 1 vs. MAS 
System 
Statistic Value ASE 
95% Confidence 
Limits 
Simple Kappa 0.7405 0.0379 0.6663 0.8148 
Weighted 
Kappa 
0.8448 0.0250 0.7958 0.8938 
 
Table 23. Kappa Statistics between Physician 2 vs. MAS System. 
 
Kappa Statistics between Physician 2 vs. MAS 
System 
Statistic Value ASE 
95% Confidence 
Limits 
Simple Kappa 0.7227 0.0391 0.6461 0.7993 
Weighted 
Kappa 
0.8274 0.0262 0.7760 0.8789 
 
 
Table 24. Kappa Statistics between Physician 1 vs. Physician 2. 
 
Kappa Statistics between Physician 1 vs. 
Physician 2 
Statistic Value ASE 
95% Confidence 
Limits 
Simple Kappa 0.5597 0.0433 0.4748 0.6446 
Weighted 
Kappa 
0.7196 0.0331 0.6547 0.7844 
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4.4 Summary 
 
I have developed a collaborative, team agent framework that aims to achieve earlier 
detection of ADR signal pairs. In this framework, a group of collaborative agents would 
search and track relevant patient information, update their knowledge and learn from each 
other in proactive way. I implemented a four-agent system using JADE and FuzzyJess 
software packages. Using real patient data, the results show that the agents worked 
together in identifying ADR signal pairs.  
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CHAPTER 5   
CONCLUSION AND FUTURE DIRECTIONS  
 
5.1  Conclusion 
In this dissertation, I developed a novel intelligent multi agent system for 
identifying adverse drug reaction signal pairs. The system offers an implementation that 
enables the agents, equipped with decision rules, to interact with each other, share their 
experiences and exchange information in a proactive way in order to identify ADR signal 
pairs. Through the study, we encounter the interesting problem of how the agents should 
collaborate to find patients in their patient databases that are similar to any given patient 
provided by one of the agents as a prototype. This leads me to develop a methodology that 
enables agents in the multi-agent system to find similar patients in agents’ databases. The 
agents are equipped with intelligent decision maker that arms them with the rule-based 
reasoning capability.  The rules used in the intelligent decision maker were developed in 
this dissertation. The agents have been supported with a cooperative learning mechanism. 
The basic idea of the learning mechanism is that the agents need to collaborate with one 
another and sharing their knowledge for the benefit of the entire agents. The agents start 
collaboration by providing their detection rules and similarity rules to the other agents. I 
proposed using a confidence level that effectively reflects the experience level of an agent 
for a given rule. This leads to a collection of rules that are the best and the most insightful 
rules which lead to improve the agents’ decision performance. The system has been tested 
using four agents. I choose four because it is representative enough while computing time 
is still reasonable.  I implemented the multi agent system using JADE and FuzzyJess 
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software packages. In the dissertation the architecture, design and implementation of the 
system has been described.  Using real patient data that involved over 20,000 patients 
treated at the Veterans Affairs Medical Center in Detroit between 2005 and 2008, two 
experiments have been performed to show how the four agents can effectively work 
together. The experiments’ results were evaluated independently by two physicians on our 
team. Kappa statistics has been to evaluate the system results.  The kappa coefficients 
show excellent agreement between the decision of physicians and the agents. This indicates 
that the agents can successfully collaborate in finding ADR signal pairs and in finding 
similar patients.   
 
5.2  Future Directions 
  
The multi-agent system can be extended step by step to move towards the 
developed MAS. Health Organization Agent and Hospital Pharmacist Assistant Agent 
could be the first two agents to be added into the system core. Health Organization Agent 
(HOA) is a broker and controller for each health organization. A HOA is the entrance point 
through which all the databases in a health organization could be accessed by outside 
institutes. Pharmacists Assistant Agents would be helpful by collecting useful information 
that help PAAs identify ADR signals. The pharmacist’s Assistant Agent role could be to 
support other agents with drugs information, ADR reporting from drug companies, and 
monitor ongoing evaluation of certain potential ADR. By having a clinical Pharmacist 
Assistant Agent, the detection and assessment of ADRs may be greatly enhanced. We can 
also develop an agent that has a role of establishing contacts with the medical records. The 
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agent should have the ability to recommend relative articles to the physicians especially 
when a decision is not certain about an ADR case.  Establishing this contact may add 
significant value to the ADR detection process.  Those medical documents will help the 
PAAs and hence its physicians in making decision.  
Another future direction is to use fuzzy measures instead of classical measures. 
Because we are dealing with deferent types of uncertain information, fuzzy measures can 
be used for the representation of uncertain information instead of classical measures. For 
example instead of using normal averaging we can use Ordered Weighted Averaging 
operators. Ordered Weighted Averaging operators change the aggregation from the 
`pessimistic' minimum-type aggregation, to the `optimistic' maximum-type aggregations. 
Also we can use type 2 fuzzy sets or interval type 2 fuzzy instead of type 1 fuzzy sets in 
order to get more precise decision.  We can also use more of machine learning techniques, 
for example classification and clustering, to make agents adaptive to their users and 
context.  This may enhance the detection speed of the PAAs. 
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ABSTRACT 
 
A MULTI-AGENT INTELLIGENT SYSTEM FOR DETECTING UNKNOWN 
ADVERSE DRUG REACTIONS THROUGH COMMUNICATION AND 
COLLABORATION 
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Advisor: Prof. Hao Ying 
Major: Electrical Engineering 
Degree: Doctor of Philosophy 
Several thousands of drugs are currently available on the U.S. market. A complete 
understanding of the safe use of drugs is not possible at the time when drug is developed or 
marketed. At that time, the safety information is only obtained from a few thousand people 
in a typical pre-marketing clinical trial. Clinical trials are not capable of detecting rare 
adverse drug reactions (ADRs) because of limitations in sample size and trial duration. 
Early detection of unknown ADRs could save lives and prevent unnecessary 
hospitalizations. Current methods largely rely on spontaneous reports which suffer from 
serious underreporting, latency, and inconsistent reporting. Thus they are not ideal for 
rapidly identifying rare ADRs. In this dissertation, I developed a team-based multi-agent 
intelligent system approach for proactively detecting potential ADR signal pairs (i.e., 
potential links between drugs and apparent adverse reactions). The basic idea is that 
intelligent agents are capable of collaborating with one another by sharing information and 
186 
 
 
knowledge which will accelerate the process of detecting ADR signal pairs. Each agent is 
equipped with a fuzzy inference engine, which enables it to find the causal relationship 
between a drug and a potential ADR (i.e., a signal pair).  The fuzzy inference uses 
detection rules developed by me in this dissertation. The detection rules are based on 
different factors. I have also developed a methodology to find similar patients in the multi-
agents system. The developed methodology uses similarity fuzzy rules in order to find 
similar patients in each agent’s patient database.  
 In this dissertation, I developed a cooperative learning mechanism that was used 
by the agents in identifying ADR signal pairs and finding similar patients. The basic idea is 
that the agents are capable of collaborating with one another by sharing their knowledge. 
The agents start collaboration by providing their knowledge (i.e. rules) to the other agents. 
Using confidence level, the most important and insightful detection rules will be found and 
used for the benefit of the entire agent system. The new updated rules will lead to improve 
the agents’ decision performance. To evaluate our approach, I designed a four–agent 
system and implemented it using JADE and FuzzyJess software packages. I choose four 
because it is representative enough while computing time is still reasonable. To assess the 
performance of the developed system, I conducted two simulation experiments that 
involved over 20,000 patients treated at the Veterans Affairs Medical Center in Detroit 
between 2005 and 2008.  From the software standpoint, the four agents collaboratively 
worked one another as designed.  Two physicians on the team independently reviewed the 
multi-agent system results. The results indicate that the agents can successfully collaborate 
in finding ADR signal pairs and finding similar patients.   
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